Bayer's Polymers segment
comprises five business groups: Plastics, Rubber, Polyurethanes,
Coatings and Colorants, including the subsidiaries Bayer Faser
GmbH (fibers).
Plastics
The Plastics Business Group supplies a broad range of engineering thermoplastics and high-tech semifinished products to meet the differing requirements of a wide variety of industries.
Films Makrofol / Bayfol PC / PC-Blends Polyamides and Polyesters Durethan A PA 66 Durethan B + T PA 6 Pocan PBT / PET Polycarbonates Apec PC-HT Makrolon PC Styrenics Bayblend PC+ABS Lustran ABS ABS Lustran SAN SAN Novodur ABS ABS Triax ABS+PA Thermoplastic Polyurethanes Desmopan TPU
Rubber
As a leading supplier of raw materials, Bayer is among the most important partners to the rubber and tire industry. The portfolio of the Rubber Business Group comprises synthetic rubber, rubber chemicals and modifiers for the plastics industry, along with special preparations and processing chemicals from Bayer subsidiary RheinChemie and latices from PolymerLatex, a joint venture with Degussa-Huls AG.
Tradename Chemical Description Abbreviation Bayer Bromobutyl Bromobutyl rubber BIIR Bayer Butyl Butyl rubber IIR Bayer Chlorobutyl Chlorobutyl rubber CIIR Baypren® Chloroprene rubber CR Buna® BL Styrene-butadiene diblock copolymers SB Buna® CB Butadiene rubber for plastic modification BR Buna® EP Ethylene-propylene rubber EPM/EPDM Buna® SL Solution styrene-butadiene rubber S-SBR Buna® VSL Solution vinyl-butadiene-styrene-butadiene rubber S-VSBR Krylene® Emulsion styrene-butadiene rubber E-SBR Krynac® Acrylonitrile-butadiene rubber NBR Krynol® Emulsion styrene-butadiene rubber E-SBR Levamelt Ethylene-vinyl acetate rubber EVM Levapren® Ethylene-vinyl acetate rubber EVM Perbunan® NT Acrylonitrile-butadiene rubber NBR Polysar® S Styrene-butadiene rubber SBR Taktene® Black masterbatches BR Taktene® Butadiene rubber for plastic modification BR Taktene® Butadiene rubber BR Therban® Hydrogenated acrylonitrile-butadiene rubber HNBR
Polyurethanes
The Polyurethanes Business Group (PU) is the world's leading supplier of polyurethane raw materials and systems. The development of new products and technologies, along with intensive customer support in all regions of the world, is an integral element of PU's strategy for success. Regional business service centers strengthen our ties to customers and accelerate business processes.
We offer our customers a comprehensive service package that includes expertise in the processing of polyurethane systems and in the design and functional performance of polyurethane products. The broad spectrum of applications for Bayer polyurethanes stretches from solid materials to foams with a wide range of properties.
Coatings and Colorants
This business group consolidates all products used as raw materials in coatings, sealants and adhesives and as colorants for plastics and construction materials.Environmental compatibility is at the forefront in the development of new products such as high-grade, high-solids and aqueous binders.
Fibers
Established in 1994 in Dormagen, Germany, Bayer Faser GmbH is one of the leading fiber manufacturers in the world. Bayer fibers are used in all kinds of products - from clothing through carpets and home furnishings to fishing lines.
2002/7/1 社内体制として発足
2002/10/1 Bayer CropScience AG 独立
2003/4/25 株主総会で分社承認 （上記CropScienceに加え）
Bayer HealthCare AG, Bayer Polymers AG and Bayer Chemicals AG.
Bayer Business Services GmbH, Bayer Technology Services GmbH
and Bayer Industry Services GmbH & Co. OHG.持株会社の下に、４事業会社、３サービス会社体制
2003/4/28 Bayer USA 新組織発表
Bayer CropScience LP, Bayer Chemicals Corporation, Bayer HealthCare LLC,
Bayer Polymers LLC and Bayer Pharmaceuticals Corporation.
Bayer Corporate and Business Services LLC.持株会社の下に、５事業会社、１サービス会社体制
（本社のHealthCareをHealthCareとPharmaceuticalsに分割）2003/10/2 バイエル ヘルスケア社、ケミカルズ社、テクノロジー サービス社が独立
2003/11 中核の化学事業分離 経営資源、医薬などに集中
2002/7/1 Bayer
New Bayer AG structure operational
Aiming for sustainable increase in corporate value / better
placed for strategic options
Effective July 1, 2002, the Bayer Group is operating within its
new organizational structure. In the future, the four operating
subgroups and three service companies ー under the umbrella of a management holding
company ー will focus more
strongly on their core competencies, making better use of growth
opportunities and aiming for a sustainable improvement in
performance. "In just seven months we have entirely
realigned the Group and adapted it to both current and future
market challenges," commented Bayer AG Management Board
Chairman Werner Wenning. "In this way we have accomplished
an important part of Bayer's restructuring."
For the moment the new structure only applies internally, with
the future legal entities still being run as organizational units
of Bayer AG. In October 2002 Bayer CropScience AG will also become legally independent ー
with retroactive economic effect
from January 1, 2002. The carve-out of the other companies is
planned to take place in July 2003 with retroactive economic
effect from January 1, 2003, after approval has been received
from the 2003 Annual Stockholder's Meeting.
This biggest reorganization in Bayer's history is designed to
enhance the Group's international competitiveness. According to
Wenning: "With this reorganization we are separating
strategic management from business operations to ensure that the
future subgroups Bayer Chemicals, Bayer CropScience, Bayer
HealthCare and Bayer Polymers
can act flexibly in their markets, make rapid, focused decisions
and capitalize more quickly on innovations." They are also
considerably better positioned for strategic options, including
cooperations, joint ventures or strategic alliances, as well as
acquisitions and divestments. "We expect the new structure
to bring a sustainable increase in corporate value ー in the interests of shareholders,
customers and employees alike," said Bayer's CEO.
In future the Bayer Group will be run by the Management Board of
the new holding company which, apart from Wenning as Chairman,
includes Klaus Kuhn (responsible for Finance), Dr. Udo Oels
(Technology and Environment), Dr. Richard Pott (Strategy and
Human Resources, labor director) and Werner Spinner (Business
Excellence, Regions and Services). The holding company will deal
with portfolio issues, strategy, budgets, finance and
appointments to the principal managerial positions.
Chairman of the Board of Management of the future Bayer HealthCare AG, which comprises the Pharmaceuticals,
Consumer Care, Diagnostics, Biological Products and Animal Health
business groups, is Dr. Frank
Morich. The Management Board Chairman of Bayer CropScience AG, which combines Bayer's crop protection
business with the recently acquired Aventis CropScience, is Dr. Jochen Wulff. Dr. Ulrich Koemm
has been appointed Chairman of the Board of Management of Bayer Chemicals AG, which comprises the current Basic and Fine Chemicals
and Specialty Products business groups along with subsidiaries H.C. Starck and
Wolff Walsrode. Dr. Hagen Noerenberg becomes Chairman of the
Board of Management for Bayer Polymers AG, which unites the activities of the
current Plastics,
Rubber, Polyurethanes, and Coatings and Colorants business
groups.
* Service
companies
Bayer Business Services,
Bayer Technology Services and Bayer Industry Services
Consent is given to the Hive-Down
and Transfer Agreements between the Company and Bayer HealthCare AG, Bayer
Polymers AG and Bayer Chemicals AG.
Consent is given to the Hive-Down
and Transfer Agreements between the Company and the service
companies Bayer
Business Services GmbH, Bayer Technology Services GmbH and Bayer
Industry Services GmbH & Co. OHG..
(Bayer USA)
April 28,2003 Bayer USA
Bayer Launches New North American Organization and New Leadership
Bayer AG shareholders voted at their annual meeting to adopt a
new organizational structure proposed by the Bayer AG Board of
Management. The proposal represents for Bayer far-reaching
changes that are expected to provide maximum operational and
strategic flexibility and meet new challenges in the marketplace
where the company competes. The company's Supervisory Board has
approved the new global structure and executive appointments.
Consistent with the global reorganization, Bayer's U.S.
subsidiary, Bayer Corporation, announced its new organizational
structure and leadership team for North America. The new
organization includes five operating companies and a service
company within a management holding structure.
In 2002, Bayer had global sales of Euros 29.6 billion, of which
approximately Euros 9 billion were from North American
operations.
Bayer's new organization in the United States comprises five
operating companies: Bayer CropScience LP, Bayer Chemicals
Corporation, Bayer HealthCare LLC, Bayer Polymers LLC and Bayer
Pharmaceuticals Corporation.
Separately, it has also created a service company, Bayer
Corporate and Business Services LLC. These six businesses are
under the umbrella of the holding company, Bayer Corporation.
As previously announced, Dr. Attila Molnar, the Senior
Representative of Bayer in North America, is President and CEO of
Bayer Corporation.
Bayer Polymers, Bayer Chemicals, Bayer Corporate and Business
Services and the Bayer Corporation holding company are based in
Pittsburgh.
Bayer's five operating companies -- CropScience, Chemicals,
HealthCare, Polymers and Pharmaceuticals -- produce a broad range
of products found in nearly every house, hospital, farm and
factory across America. Its products help diagnose and treat
diseases, purify water, preserve local landmarks, protect crops,
advance automobile safety and durability and improve people's
lives.
One of Fortune magazine's Most Admired Companies, Bayer promotes
science literacy and hands-on education through its Making
Science Make Sense educational initiative. Approximately 5
percent of Bayer's 21,600 employees volunteer in local schools,
and more than 500 charitable organizations receive funding from
the Bayer Foundation. In 2002, Bayer's diversity efforts were
honored with the Catalyst Award for its Women: Leaders for the
Global Marketplace program.
The worldwide Bayer Group is based in Leverkusen, Germany, and
has some 120,000 employees. Its stock is a component of the DAX
and is listed on the New York Stock Exchange (ticker symbol:
BAY).
2002年10月03日 Chemnet Tokyo
バイエル、EQTに子会社の香料メーカー売却完了
バイエルは3日、子会社の香料メーカーであるハーマン・アンド・ライマー社（H＆R）をEQTノーザン・ヨーロッパ・プライベート・エクイティ・ファンズ（EQT）に売却したと発表した。200年10月1日に契約、即時に発効し、EQTはH＆Rを取得した。バイエルは売却益を債務削減にあてる。
バイエルグループは、H＆Rの売却により事業ポートフォリオの合理化を一段と加速させた。この数ヶ月間にバイエルは住宅部門、アグファ社の株式、フランス、スペインの後発医薬品事業などの売却を行なってきた。さらに近くラインケミー、ポリマーラテックス両社および家庭用殺虫剤事業も売却する予定だという。
October 1, 2002
Portfolio streamlining continues
Bayer divests Haarmann & Reimer
Bayer AG, Leverkusen, has sold its non-core Haarmann & Reimer subsidiary to the EQT Northern Europe Private Equity Funds. Closing of the deal today, October 1, 2002, means EQT acquires the business of the Holzminden, Germany-based fragrances and flavors manufacturer with immediate effect. Bayer will use the proceeds to reduce net debt.
The sale marks the completion of another stage in the streamlining of the Bayer Group's business portfolio. In recent months Bayer already divested company housing units, the interest in Agfa and the generics business in France and Spain. The further planned divestments of Rhein Chemie, PolymerLatex and the household insecticides business are expected to be accomplished in the near future.
October 4, 2002
Bayer plans to sell Rhein
Chemie to Advent
International → 売却取り止め
Transfer scheduled
for November 2002
Bayer AG intends to
sell its subsidiary Rhein Chemie Rheinau GmbH, Mannheim, Germany,
to a group of financial investors advised by Advent International
Corporation, Boston, for EUR 215 million, including the
assumption of debt. The transaction would include the wholly
owned subsidiary iSL-Chemie GmbH & Co. KG of Kurten, Germany,
as well as Rhein Chemie affiliates in the United States and Japan
and a Chinese joint venture in which Rhein Chemie owns a 90
percent interest. It is planned to complete the sale at the
beginning of November, subject to the approval of the relevant
antitrust authorities.
"Under this new
ownership, Rhein Chemie would have excellent prospects of further
expanding its strong market position," commented Bayer AG
Management Board Chairman Werner Wenning. In December 2001, Bayer
announced its intention to divest Rhein Chemie and other
subsidiaries so as to focus more closely on its core businesses.
The sale of Holzminden, Germany-based subsidiary Haarmann &
Reimer to the financial investor EQT was completed only a few
days ago.
Founded in 1889,
Rhein Chemie has been a subsidiary of Bayer AG since 1971. The
company is an internationally successful supplier of specialties
to the rubber, lubricant and plastic industries. Its 1,100
employees in Germany and around the world, including 550 in
Mannheim, generated global sales in 2001 of approximately EUR 320
million. Rhein Chemie operates production facilities in Germany,
the United States, China, Japan and other countries.
With more than 50
investments worldwide in the chemical and pharmaceutical
industry, Advent International Corporation has extensive
experience in this sector. Its investments in European companies
include Vinnolit in Germany, Materis in France and Pemco in
Belgium.
Advent International
is one of the world's largest private equity firms with EUR 6
billion under management and offices in 14 countries. The company
employs more than 100 experts in the United States, Europe, Latin
America and Asia. Since its founding in 1984, Advent
International has invested in over 500 companies. The chemical
and pharmaceutical sector is one of Advent International's main
fields of expertise in Europe.
December 5, 2002 Bayer
Strategic options for Rhein Chemie under review
An agreement concluded in October 2002 between a U.S. financial investor and Bayer concerning the sale of Rhein Chemie has been dissolved by common consent of the parties, who were unable to agree on a number of outstanding points. Various strategic options are currently being considered.
Rhein Chemie is an internationally successful supplier of specialties to the rubber, lubricant and plastics industries. It also has a wholly owned subsidiary, iSL-Chemie GmbH & Co. KG in Kurten, Germany, affiliates in the United States and Japan, and owns a 90 percent interest in a joint venture in China.
March 26, 2003 Financial Times
Bayer to keep Rhein Chemie.
After looking for a buyer for 15 months, Bayer AG of Leverkusen, Germany, has decided not to sell its Rhein Chemie Rheinau GmbH subsidiary. A $212 M deal with the US equity form Advent International Corp fell through in Dec 2002. Rhein Chemie has been a Bayer subsidiary since 1971, employs 1100 people and had sales of $275 M in 2002. The company supplies products for the plastics industry, including release agents, vulcanisation agents and polymer-bound chemicals. The company also distributes Bayer's rubber polymer and rubber chemical products in the USA. It is likely to remain operating as an independent unit rather than joining the new Bayer Polymers AG structure.
独バイエル 渦中の医薬継続 「総合化学」維持
道探る 「内向き」志向の改革カギ
独バイエルが高脂血症治療薬「バイコール」の副作用事故で揺れる医薬事業の継続を決めた。事故後の情報開示の遅れも手伝って信用を失ったが、低成長の化学事業だけでは世界大手として生き残れないと判断したからだ。ＢＡＳＦ、ヘキスト（現アベンティス）を加えたかつての「独三大化学」の中で、化学・医薬の両立にこだわる同社の総合路線が問われる。
「挫折を味わったが、医薬は今後も中核事業」ーー。米同時テロの衝撃が冷めない９月１３日、バイエルのマンフレッド・シュナイダー社長は、いったんは検討した医薬事業の売却を撤回した。
米で「副作用死者」
最高意思決定機関の監査役会は同日、医薬事業を保持すると決定。生え抜きのべルナー・ベニング取締役最高財務責任者を２００２年４月に次期社長にすることも決めた。監査役会会長に就任予定のシュナイダー社長は「１０年の任期満了に伴う交代」を強調。「バイコール」の副作用事故による引責辞任説を否定した。同社株価はその後一段と下げた。
挫折の発端は、米食品医薬品局（ＦＤＡ）が８月発表した「副作用と見られる米国の死者３１人」という報告。同薬品の全面回収を余儀なくされたほか、政府への情報開示の遅れから独検察庁が薬事法違反の疑いで捜査に乗り出し、消費者の信用も失墜した。
同社の医薬の売上高比率は３２％。バイコールは年２倍近い増収を続けただけに、今年１２月期の営業利益が前期比大幅減の見通しとなる打撃を受けた。
労組が売却反対
日本のエイズ薬害にみるように、信用を失った医薬事業の存続は難しい。同社は死亡事故が表面化した後、「出資比率が５割を切ることも辞さない」と、競合２社と医薬部門の売却交渉に入った。それを土壇場で撤回した裏には、労組幹部らが「百年の伝統を持つ医薬事業は保持すべきだ」と、雇用・国益面から売却を反対したことがある。
労使折半参加の監査役会が、協調を重視する余り、「大胆な改革を妨げた」との指摘もある。一般株主の利害が二の次になりがちな監査役会制度は独国内でも批判がある。ダイムラークライスラーは９月、北米部門の不振を十分監視できなかった反省から、監査役会の否定にもつながる社外取締役による米国型の経営評議会の発足を決めている。
化学と異なる性格
バイエルは化学を低成長ながら安定収益源とした上で、医薬を高成長部門に位置付けてきた。だが、規模の効果を追求する装置産業の化学と、知識集約型の医薬は性格が異なる。医薬の場合、先端技術の吸収は米国での買収・投資戦略に負う部分が大きい。米診断薬メーカーに出資したほかゲノム分野の提携先も多い。診断薬の本部も米国にある。市場・開発の両面で米依存が強いだけに、英米型の厳しいルールの中で勝負するほかない。
一方で、化学事業は独大手銀行との連携を通じて大型投資をしてきた歴史がある。金融機関の株式保有率が過半数に達する中で、ドイツ的な企業統治も変えにくい。米独のこの溝を埋めない限り、米市場での摩擦は続く。副作用による最も多くの死者が出た米国で複数の賠償訴訟が発生。ニューヨーク証券取引所への株式上場も来年に延期した。 バイエルは９月、ＦＤＡに男性用性的不全治療薬の新薬承認を申請し、新たな事業拡大を狙っている。だが、責任追及と抜本改革を怠れば再び対応を誤る懸念も残る。
他メーカー 得意分野に特化
「三大化学」と呼ばれ、独経済の屋台骨だったＢＡＳＦ、バイエル、ヘキスト。だが、総合化学メーカーと呼べる独企業は今やバイエルだけとなった。売上高で世界最大の化学メーカー、ＢＡＳＦは今年３月に投資がかさむ医薬部門を売却し、化学専業に転換した。ヘキストは仏ローヌ・プーランとの合併で生命科学大手のアベンティスに変わった。
３社を含む独化学５社は１９２５年、合併によって「ＩＧファルベン」を形成、ナチス時代に世界最大の総合化学コンツェルンに発展した。戦後の集中排除で再び３社に分かれたが、目指したのは複数分野を網羅した総合化学大手だった。
だが、グローバル競争の進展に伴い投資規模が膨らみ、同業他社は得意分野に事業を集中し始める。その中でバイエルはアベンティスから遺伝子組み替え技術を含む農薬部門を買収することで合意。業容拡大策は不変だ。業績が悪化していても、継続投資を要する先端分野をどこまでカバーできるかが焦点となる。
October 28, 2002 Bayer
Bayer CropScience AG to sell a range
of products to BASF
Company on track with regulatory divestments
subsequent to acquisition of Aventis CropScience
Bayer CropScience AG today announced
that it intends to sell a package of selected insecticides and
fungicides to BASF AG while retaining certain back-licenses for
non-agricultural applications. The total package is valued at EUR
1,330 million. Taking into consideration the back-licenses the
cash purchase price amounts to EUR 1,185 million. With the
completion of the envisaged transaction, Bayer CropScience would
fulfill within the given timeframe a major condition imposed by
the European Commission and the U.S. Federal Trade Commission
(FTC) as part of the Aventis CropScience acquisition. This
transaction is subject to the approval by the European Commission
and the U.S. Federal Trade Commission.
Following the respective consent
orders the agreements with BASF contain assets and rights related
to two insecticides (active ingredients: Fipronil, Ethiprole) and
a number of fungicides (active ingredients: Prochloraz,
Iprodione, Triticonazole, Fluquinconazole and Pyrimethanil) for
certain regions and application fields. BASF will also acquire
the Aventis CropScience manufacturing plant in Elbeuf, France.
The total revenue from the products and operations involved in
the transaction amounted to about EUR 500 million in 2001.
"After the sale of these
products, Bayer CropScience can now focus entirely on developing
its business and expanding its market position", said Werner
Wenning, Chairman of the Board of Management of Bayer AG.
"Cash-in from the sale also
contributes to improving the Group´s financials, as does the cash inflow from
the other divestments we have already announced."
"Following a very competitive
auction process and intensive negotiations with several
interested parties we are pleased to have reached an agreement
with BASF," added Dr. Jochen Wulff, Chairman of the Board of
Management of Bayer CropScience AG. "The purchase price
agreed represents a fair compensation for the required
divestments. I am also pleased that we were able to retain
licence rights to market Fipronil and its mixtures in certain
non-agricultural markets within the scope of the FTC consent
order," emphasized Wulff. "The integration of the
Aventis CropScience operations is moving ahead quite rapidly and
we continue to focus our efforts on the further integration and
strategic development of the new Bayer CropScience."
Bayer CropScience AG, a subsidiary
of Bayer AG with annual sales of some EUR 6.5 billion, is one of
the world's leading innovative crop science companies in the
areas of crop protection, seeds and green biotechnology, as well
as non-agricultural pest control. The company offers an
outstanding range of products and extensive service backup for
modern, sustainable agriculture and for non-agricultural
applications. Bayer CropScience has a global workforce of 22,000
and is represented in 122 countries, ensuring proximity to
dealers and consumers.
Chemnet Tokyo 2003/03/06 発表文
バイエル、ポリマ−ラテックス社の売却決る
バイエルは6日、デグサ社との折半出資会社であるポリマーラテックス社（本社:ドイツ）を金融投資会社のソロス・プライベートエクイティ・パートナーズ社に売却すると発表した。売却金額は約2億3,500万ユーロ。
バイエルはこれまでに子会社ハーマンアンドライマーをはじめ、アグファ社株式の30％、バイエル社の社宅、ジェネリック医薬品、家庭用殺虫剤事業などの売却、整理を行ってきたが、今回のポリマーラテックス社の売却により、一連の戦略的再編プロジェクトを完了する。
2003/3/4 Bayer
Bayer and Degussa
sell PolymerLatex to Soros Private Equity Partners
Bayer AG of
Leverkusen, Germany, and Degussa AG of Dusseldorf, Germany, are
selling PolymerLatex GmbH & Co. KG, their Marl, Germany-based
50:50 joint venture, to the financial investment company Soros
Private Equity Partners. The sales price amounts to approx. 235
million euros. The transaction is subject to the approval of the
relevant antitrust authorities.
The sale of
PolymerLatex completes the divestment program which Bayer
launched at the end of 2001 as part of its Group-wide
reorganization and strategic realignment project. The divestments
included the subsidiary Haarmann & Reimer, the 30 percent
interest in Agfa, a large proportion of the Bayer company
apartments, the generics business in France and Spain and the
household insecticide business. In addition, Bayer sold off numerous crop
protection products and active ingredients which had to be
divested or licensed out as a result of conditions imposed by the
anti-trust authorities following the take-over of Aventis
CropScience. Through the cash inflow from the divestment program
Bayer has been able to cut its net debt, which had increased
significantly in 2001 through the acquisition of Aventis
CropScience, to less than 10 billion euros by the end of 2002.
In fiscal 2001,
PolymerLatex generated sales of 344 million euros with about 730
employees. The joint venture, which was founded in 1996 by
Degussa and Bayer, produces latex products in the paper,
carpet/moulded foam and speciality applications fields, and holds
a leading position among latex suppliers. PolymerLatex has been
able to expand its leading market position even further over the
past few years thanks to significant investments in its five
European production sites, and continuous development of
customized products.
Soros Private Equity
Partners ("Soros") is a global private equity investor
which, together with its affiliates, currently manages in excess
of US-Dollar 4 billion of equity capital. Soros has announced
that it intends to develop PolymerLatex's operations in the
coming years and will consider possible add-on-acquisitions to
consolidate its market share.
Bayer is an
international, research-based group with major businesses in
health care, crop science, polymers and specialty chemicals. For
2001, the group recorded sales of 30.3 billion euros. Capital
expenditures totaled 2.6 billion euros in 2001 and 2.6 billion
euros were invested in research and development. The total number
of employees worldwide at the end of September 2002 amounted to
about 123.500. For more information visit www.bayer.com.
日本のバイエル、組織改革進む
バイエル ケミカルズ ジャパン株式会社を７月１日に設立
バイエルグループ、世界および日本における化学品事業を更に強化
バイエル株式会社（本社：東京都港区、社長：ミヒャエル・ポートフ）は、２００３年７月１日付で、同社の基礎・精密化学品およびスペシャリティ製品等の化学製品を取り扱う事業部門を新設分割の方法により、全額出資子会社としてバイエル ケミカルズ ジャパン株式会社を設立する。代表取締役社長には、バイエル（株）日本・韓国バイエル ケミカルズ代表のエッカード・ベンデロートが就任する。なお、新会社の所在地はバイエル（株）に同じ。
これに伴い、同事業部門の従業員は同日付で全員新会社に移籍する。
また、バイエル（株）が所有している豊橋事業所（愛知県豊橋市）を従業員を含めバイエル ケミカルズ ジャパン（株）に移管する。同事業所は、物流センターおよび顧客技術サービスセンターとして、紙パ用化学品、繊維加工用化学品、およびイオン交換樹脂などの試験施設を擁している。
今回の組織改革は、バイエルグループが世界規模で推進している戦略的な４事業部門の再編の一環として実施される。本改革は、ヘルスケア、農薬、高分子材料、化学品の各事業の独立性の拡大と世界市場における競争力の維持・強化を目的としたもの。なお、バイエルグループ（ドイツ）においても本年中に化学品事業を担うバイエル ケミカルズ社が独立子会社として発足し、ドイツ・バイエル社が持株会社として運営する予定。
バイエルグループの化学品事業の売上は、３３億ユーロ（２００２年）で、すでに世界的なリーダーとしてのポジションを確立している。一方、日本における化学品事業グループは、基礎・精密化学品およびスペシャリティ製品等の化学製品を取り扱う化学品事業部門とＨ．Ｃ．スタルクで構成されており、売上は３３０億円（２００２年）。化学品事業部門は、１１ユニットで構成されており、中間体製品、添加剤、着色剤や技術ソリューションを多岐に渡る産業に提供している。バイエルの化学品事業グループの商品や業績の詳細はホームページ http://www.bayerchemicals.com （英語）にて閲覧可能。
Ｈ．Ｃ． スタルク社は、ドイツ・バイエル社の関連企業であり、世界各地で耐熱性金属やスペシャリティ製品の生産・販売をしている。日本においては、日本のバイエルのグループ企業であるスタルク ヴイテック（株）が同事業を引き続き行なう。
| バイエル ケミカルズ ジャパン株式会社概要 | |||
| 会社名称 | ： | バイエル ケミカルズ ジャパン株式会社（Bayer Chemicals Japan Ltd.） | |
| 設立日 | ： | ２００３年７月１日 | |
| 資本金 | ： | ４億円 （バイエル株式会社１００％出資） | |
| 従業員数 | ： | ６１名 | |
| 事業内容 | ： | 有機・無機化学品原材料の輸入・販売・スペシャリティ製品に関する研究 および技術サポート |
|
| 本社 | ： | 東京都港区高輪４丁目１０番８号 | |
| 事業所 | ： | 豊橋事業所（愛知県豊橋市） 顧客技術サービスセンター（愛知県豊橋市）--- イオン交換樹脂ラボ、紙パ用化学品ラボ、繊維加工用化学品ラボ 顧客技術サービスセンター（兵庫県姫路市）--- 皮革用化学品ラボ |
|
| 役員 | ： | 代表取締役社長 エッカード・ベンデロート 取締役 ミヒャエル・ポートフ 取締役 ブルース・オルソン |
|
China Chemical Reporter
2003/7/29
Bayer Plans to
Invest in the Construction of a HDI Project in Shanghai
Bayer of Germany has
signed with Shanghai Chemical Industry Development Zone an MOU on
the construction of a 30 000 - 50 000 t/a HDI (hexamethylene
diisocyanate) project in the next 3 years. Bayer is one of the
first chemical giants launching projects in Shanghai Chemical
Industry Development Zone and has so far put a total investment
of over US$3.0 billion. The coating project starting construction
by Bayer in January 2001 has been completed and put on stream and
the annual output value of the project can hopefully reach RMB150
million. The polycarbonate project jointly funded by Bayer and
Shanghai Chlor-alkali Chemical Industrial Co., Ltd. will start
construction in the fourth quarter this year. Preparations of the
MDI/TDI project that has already been approved are also under
way. Bayer has a keen interest in the increasing market of
high-tech chemical products in China and intends to make further
investments in the integrated base in Shanghai. According to the
MOU, Bayer will construct a 30 000 - 50 000 t/a HDI unit in the
compounds of its coating plant and put the project on stream in
2006. HDI is a major raw material for coatings and adhesives
produced in Bayer Coating Co., Ltd.
August 11, 2003 Bayer Polymers
Asian center for high performance coating raw materials
Bayer Polymers plans large-scale investments at its Caojing,
China, site
Bayer Polymers, a division of Bayer AG, plans to expand its
Caojing site near Shanghai, China, making it Bayer Polymers' most
important production facility for coating raw materials in the
Asia Pacific region. Production plants for aliphatic (脂肪族) and aromatic polyisocyanates as well as the monomer hexamethylene
diisocyanate (HDI) will be
constructed in three phases at the Shanghai Chemical Industry
Park. This project is being managed by Bayer Coatings Systems
Shanghai Company Limited (BCSS), a wholly-owned Bayer subsidiary
that develops, produces and markets raw materials for coatings
and adhesives and also provides associated technical services.
"The demand for raw materials for the manufacture of high
performance polyurethane coatings is growing strongly in this
region. With this large-scale investment program, we aim to
optimally exploit the excellent market opportunities there,"
says Dr. Joachim Wolff, Senior Vice President of Global
Operations Base and Modified Isocyanates (BMI) at Bayer Polymers,
"We expect our coating raw materials business to continue
its outstanding performance because the coatings formulated from
these products satisfy highest requirements with respect to
appearance, chemical resistance, mechanical strength,
lightfastness and weather stability.
In April 2003, a plant with an annual capacity of 11,500 tons was
brought on line for the production of the Desmodur® N line of aliphatic
polyisocyanates, a segment in
which Bayer Polymers holds a leading position. These raw
materials are used primarily in the formulation of general
industrial and automotive refinishing coatings, as well as
coatings for plastics.
A production plant for the Desmodur® L line of aromatic polyisocyanates is currently under construction. These
raw materials have proved ideal for the formulation of high
performance polyurethane coatings, e.g. for wood and furniture.
With the start of operation of this plant in late 2004, Bayer
Polymers will have a total capacity of 11,000 tons for Desmodur® L
products at the Caojing site, enabling Bayer Polymers to maintain
its strong position in the field of low-monomer raw materials for
these coating systems. Bayer Polymers' goal is to be the first
local producer of low-monomer TDI adducts in support of a Chinese
government initiative to reduce the free TDI content in wood and
furniture coating systems for interior applications.
The third project is the construction of a plant for the
production of
HDI,
which is used as a raw material for aliphatic polyisocyanates.
The plant will ultimately have a total capacity of 50,000 tons,
with 30,000 tons available by 2006. Capacity can be expanded by
roughly 20,000 tons in a second phase of construction if
warranted by market growth in the region.
2003年10月2日 バイエル株式会社
バイエルグループの組織再編進む
バイエル ヘルスケア社、バイエル
ケミカルズ社、バイエル テクノロジー
サービス社が独立
http://www.bayer.co.jp/bgj/newsfile/news/news-190_j.html
バイエル（本社：ドイツ、レバクーゼン、社長：ヴェルナー・ヴェニング）は、2003年9月30日、バイエル
ヘルスケア社、バイエル
ケミカルズ社、およびバイエル テクノロジー
サービス社が、商業登記を終え、法的に独立子会社になったことを発表した。これは、2002年よりバイエルグループ全体で始まった組織改革の一環であり、2003年末までには事業グループのバイエル
ポリマーズと、サービス事業部のバイエル
ビジネス サービスおよびバイエル
インダストリー サービスも独立を完了する予定。すでに2002年10月1日には、バイエル
クロップサイエンス社が独立子会社として事業を開始している。
ドイツ・バイエル社のヴェニング社長は、「今回の組織再編は将来の成功に向けたさらなる一歩である。新しい企業構造によって子会社の個々の責任が強化され、より柔軟な体制になる。当社の狙いは、各社の潜在能力を存分に活用し、価値創出と持続的な業績向上を実現することにある」と語った。
バイエル
ヘルスケア社は、医療用医薬品、バイオロジカルプロダクト、コンシューマーケア、診断薬、動物用薬品の5分野から成り、世界各地でヘルスケア事業を展開している。バイエル
ヘルスケアは現在、世界各地に約34,000人の社員を擁しており、2002年の売上高は94億ユーロ。バイエル
ヘルスケア社のロルフ・クラッソン社長は、「バイエル
ヘルスケアは、人間と動物の健康にかかわる広範な製品群を提供している。当社の強みは、高い競争力を持つ広範な製品ポートフォリオだ。当社の5部門中4部門がそれぞれの市場で上位5社に入っている。当社は良好なスタート地点に立っており、ここからさらに強力なヘルスケア事業を構築していく」と述べている。
バイエル
ケミカルズ社は、革新的なスペシャリティ化学品の大手企業であり、世界130地域に約14,500人の社員を擁している。バイエル
ケミカルズには既存のバイエルの化学品事業と子会社ウォルフ・ワルスローデが含まれており、H.C.スタルク社の事業運営も担当する。製品群は、染料、紙・パルプ用化学品、皮革用化学品、繊維加工用化学品、機能性化学品、医薬品・農薬向け中間体など多岐にわたる。2002年の売上高は33億ユーロ。バイエル
ケミカルズ社のウルリッヒ・ケム社長は「当社は、技術を革新し、常に前進する企業である。高品質の製品と第一級の顧客サービスによって、当社は長期的な成功の基盤を固めつつある」と語っている。
バイエル テクノロジー
サービス社は世界中で事業展開しており、化学品および医療用医薬品生産施設の開発、計画、建設、そして工程の最適化を担当している。ドイツ、レバクーゼンに本社を置き、テキサス州ベイタウン（米国）、メキシコシティ（メキシコ）、サンパウロ（ブラジル）、上海（中国）に地域事務所を設置している。全従業員数は2,300人。2002年の売上は6億9,000万ユーロ。バイエル
テクノロジー
サービス社のウォルフラム・ヴァーグナー社長は「我々は、技術革新と費用効果の高いソリューションを提供し、顧客の世界的な利益の確保と拡大を手助けすることを目的としている。この新会社の設立により、約2,300人の技術者と科学者が数十年にわたって蓄積してきた経験と専門知識が、さらに広範な社外の顧客にも利用可能となった」と述べている。
バイエルについて
バイエルは、ヘルスケア、農薬、高分子材料および化学品の4つの事業グループを柱に持つ、研究開発を基礎とする国際的な企業グループ。全世界の従業員数は122,600人(2002年末)。
グループ全体の2002年の売上は296億ユーロ、純利益は11億ユーロを計上した。
日本のバイエルについて
日本においてバイエルは、発売以来すでに100年以上経過している解熱・鎮痛剤「アスピリン」を発明した会社として知られている。
日本のバイエルは、ヘルスケア、農薬、高分子材料および化学品事業を展開している。
日本におけるバイエルグループ全体の2002年の売上げは2,110億円で、従業員数は約2,900名。
バイエルにとって、日本は世界第3位の市場。
日本経済新聞 2003/11/8
発表
独バイエル 中核の化学事業分離 経営資源、医薬などに集中
独バイエルは７日、ポリマーと化学事業部門を再編して新会社を設立し、２００５年初めまでに株式上場させると発表した。化学部門の各種中間剤や繊維・製紙化学製品などをポリマー部門と統合し、新会社をつくる。中核の化学事業を分離独立させ、バイエル本体は医薬や農業化学など開発投資がかさむ事業に経営資源を集中する。
バイエルは今年から統括会社が４事業子会社を管理する体制を敷いた。医薬を含むヘルスケア、農業化学、ポリマー、化学の４子会社がある。このうちポリマー子会社を中核にして化学子会社の一部事業を統合し、新会社「NewCo（ニューコ）」を設立する。
新会社の年売上高は５６億ユーロ（約７１７０億円）、従業員は２万人になる見通し。新会社を０５年初めまでに上場させて、統括会社を核にしたバイエルグループの経営から切り離す。
主要な化学事業の分離に伴いバイエルグループはヘルスケア、農業化学、素材科学という新たな３事業子会社体制に変わる。同グループの売上高は現在よりも約２０％減って約２２０億ユーロになる。新会社上場による売却益はこれら３事業分野に集中投資する。特に医薬や農業化学分野は開発費用がかさむ傾向にあり、３つの事業に特化して投資効率を高める狙いだ。
Werner Wenning continues
systematic realignment:
Bayer plans stock
market flotation for chemicals activities and strategic refocus
of health care business
http://www.press.bayer.com/News/News.nsf/id/0029E5ECD27BC2F7C1256DD70043DABF
Supervisory Board
approves Management Board plans /
Focus on core
businesses should enhance Bayer's competitiveness /
New company to be
positioned among Europe's leading chemical enterprises /
Pharmaceuticals
business to be retained as stand-alone solution
Following its
successful reorganization, the Bayer Group intends to maintain
its focus on its core businesses and in the future concentrate on
health care, nutrition and innovative materials. For this reason, Bayer
Chemicals (excluding H.C. Starck and Wolff Walsrode) is to be
combined with certain parts of the polymers business in a new
company with the provisional name "NewCo". The aim is for this company to
be listed on the stock market under a new name by early 2005 at
the latest. The Supervisory Board approved these plans of the
Group Management Board at its meeting today. CEO designate of the
new company is Dr. Axel Claus Heitmann (44), currently a member
of the Executive Committee of Bayer Polymers and head of that
company's Asia region, headquartered in Shanghai.
"Both Bayer and
NewCo will benefit from the split, because a stock market listing
will be highly attractive for both shareholders and
employees," explained Bayer CEO Werner Wenning.
"Following the separation, Bayer ー with sales of around EUR 22
billion ー will be able to focus more closely on the
core businesses in which we have excellent technologies, strong
market positions and above all growth areas that we intend to
further strengthen by pooling all our resources. In this way, we
aim to safeguard the success of our company in the long term and
generate additional value. Bayer's reorganization was a key
requirement for this significant step. Equally, we will be
safeguarding the future of our chemicals business because, as an
independent company, NewCo will be able to respond faster and
more flexibly. In this new scenario, chemicals and polymers will
be the core businesses and therefore the top priorities of the
company's new management team."
In the future Bayer
aims to concentrate all its financial and management resources on
developing and expanding its core activities in health care,
nutrition and innovative materials, which are predominantly
research-intensive areas. Wenning sees high growth potential in
these areas but also a corresponding need for investment.
"This means we do not have sufficient resources available to
maintain or enhance the market positions of our chemicals
business or all of our polymers activities," said Bayer's
CEO. The separation should trigger the necessary entrepreneurial
impulses and create the conditions for optimizing the strategies
of each company according to their different business needs.
Bayer's wealth of
knowledge with respect to humans, animals, plants and materials,
coupled with the respective products, will provide the foundation
for sustainable growth in the long term in the promising markets
in which Bayer plans to specialize. Following the reorganization,
Bayer will have three operating subgroups: Bayer HealthCare,
Bayer CropScience and Bayer MaterialScience.
Growth will come
primarily from products containing newly researched active
ingredients, from the consumer healthcare business and from
growth in Asia. However, contributions to value creation should
be achieved by the Group-wide utilization of technology
platforms, nanotechnology and the expansion of biotechnology and
genetic engineering as key innovation drivers.
Biotechnology is
used not only by CropScience to achieve sustainable qualitative
improvements in food crops and higher yields, but also to open up
a range of new applications in other areas such as gene-based
diagnostics.
Bayer's new
realignment also includes repositioning the Pharmaceuticals
business. "We
have examined all the options for this business ー especially
the possibility of partnerships. We found that none of these
solutions would have adequately reflected the value of our
Pharmaceuticals business. In our view, they would not have
offered a value-creating alternative," explained Werner
Wenning. "We therefore intend to focus on our own
strengths and steer our Pharmaceuticals Division with
significantly modified structures towards a successful future." Bayer will concentrate its
research effort on the therapeutic areas where it already plays a
leading role and has developed successful products:
anti-infectives, cardiovascular (including diabetes and obesity)
and urology. Bayer also has a number of promising product
developments in the oncology (cancer) field.
"We intend to
position our Pharmaceuticals Division as a mid-size European
pharmaceuticals business because we are convinced that this will
generate the greatest value for our shareholders," stated
Wenning. In the future, the division's activities will be focused
more strongly on Europe, though without neglecting the important
markets in the United States and Asia. According to Wenning,
considerable progress has already been made in restructuring
Pharmaceuticals. Successful new product launches have given
grounds for optimism. For example, sales of LevitraR, Bayer's
treatment for erectile dysfunction, are very encouraging. Also,
major progress has been made in the area of cancer research. A
raf kinase inhibitor for the treatment of advanced renal cell
carcinoma, developed in collaboration with U.S. company Onyx, has
now entered phase III clinical trials.
Wenning also sees
particular opportunities for growth in the consumer
healthcare business.
Bayer's Consumer Care, Diagnostics and Animal Health divisions
hold strong or very strong positions worldwide. The company
intends to further expand these activities.
The
CropScience business units
Herbicides, Insecticides, Fungicides and Seed Treatment hold
excellent positions, and the aim is to grow faster than the
market in these areas. Environmental Science is the market leader
in the supply of pest control products for the home and garden.
The Bio Science unit is a pool of impressive expertise in the
field of biotechnology for which experts predict annual growth
rates of 15 percent.
In MaterialScience, Bayer holds global leadership
positions in polyurethanes, polycarbonates and coating raw
materials. It has access to internationally acknowledged
leading-edge technologies and a wealth of expertise acquired over
many years. It is intended to continue expanding the growth areas
of innovative plastics and coatings materials ー with a
special investment focus on the growth markets of Asia. In China
alone, Bayer is currently building or planning several new
production facilities. The MaterialScience subgroup will in
future also include the subsidiaries H.C. Starck and Wolff
Walsrode.
In addition to these
three operating subgroups, the three service companies will also
remain within the Bayer Group. These companies will also perform
services for NewCo. Employees of the service companies whose work
centers on areas that will be part of NewCo are to be transferred
to NewCo.
With sales of EUR
5.6 billion and a workforce of around 20,000, NewCo will rank
among Europe's leading chemicals suppliers, occupy leadership
positions in more than two thirds of global market segments and
be a technology leader in manufacturing. "Independence will
trigger strong entrepreneurial impulses, enabling NewCo to
enhance the competitiveness of its production technology, too,
and generate above-average growth and value," said Wenning.
Independence from
Bayer should put NewCo in a position to utilize capital resources
more efficiently for the enhancement of its competitiveness and
to seek partners or investors at its discretion. The new
structure will also make it easier to focus management resources
on the specific needs of the chemicals business, conform
structures and processes to the requirements of the chemical
industry and activate niche markets utilizing new business
models. The aim is to continue to grow through a stronger focus
on innovation, efficient use of resources and targeted expansion
of attractive specialty applications.
NewCo will have a
broad-based portfolio of around 5,000 products covering basic,
specialty and fine chemicals as well as polymers. These products
include: intermediates for the manufacture of active ingredients
for pharmaceuticals and crop protection products; material
protection products; chemicals for the leather, textile and paper
industries; ion exchange resins for water treatment applications;
inorganic pigments for coloring concrete and plastics; polymer
additives such as flame-retarding agents and plasticizers; solid
rubber and rubber chemicals for the rubber and tire industries;
ABS (styrenics) and semi-crystalline thermoplastics which are
used primarily in automotive engineering, as well as for the
manufacture of covers and housings. NewCo will have a global
presence with production facilities and sales organizations in 40
companies and 20 countries.
Media briefing on November 26,
2003, Shanghai, China
http://www.news.bayer.com/News/News.nsf/id/29E09CD16BF08DC6C1256DE90037A77C
"Photo: Bayer MaterialScience"
2003/12/15 Bayer
バイエル、約22億ユーロの減損費用を計上
キャッシュフローと配当支払い能力には影響なし
バイエル（本社：ドイツ、レバクーゼン、社長：ヴェルナー・ヴェニング）は、2003年第4四半期（2003年9月〜12月）に合計22億ユーロの資産減損費用(asset impairment
charges) を計上することになった。この費用は、製品群の戦略的な再編、分社化が決定した新会社（化学品事業と一部の高分子材料事業より構成）の株式上場計画、並びに今後のバイエル
マテリアルサイエンス事業グループの経営条件の変化と関係している。なお、金利・税金支払い前収益（EBIT）へのこれら特別項目の影響は約20億ユーロになると予想されており、営業外収益は約2億ユーロ減少する見込み。
高分子、化学品事業における資産減損費用は、17億ユーロに上る見込みで、その大半は分社化される新会社に移転される事業活動に関係している。なお、この金額には、現在進行中の効率改善プログラムの一環である施設統合の費用も含まれている。
バイエル ヘルスケア事業グループは約5億ユーロの資産減損費用を計上する予定で、その一部は医療用医薬品研究施設の統合と関連している。
営業外収益関連での資産減損費用は、ダイスター社およびバイオリサーチ会社であるキュラジェン社が保有する株式の評価引き下げから発生する。
この減損費用は現金収支を伴わない会計項目であり、この引当金はキャッシュフローにもドイツ・バイエル社の配当支払い能力にも影響を及ぼさない。
この資産減損費用を考慮し、バイエルグループは2003年通年ではマイナスのEBIT並びに純損失を計上すると予想している。しかし、バイエルは引き続き、同特別項目計上前のEBITはこれまでの予想どおり二桁増になると見込んでいる。
December 11, 2003 Bayer
Bayer and DuPont
expand leading position in engineering thermoplastics
Dedication of
world-scale plant for the production of polybutylene
terephthalate (PBT)
Operator is
the joint venture DuBay Polymer GmbH / Total investment 50
million euros / Annual capacity: 80,000 tons
http://www.news.bayer.com/News/News.nsf/id/2003-0589
With the dedication of a
world-scale plant for the production of polybutylene
terephthalate (PBT)
in Hamm-Uentrop, Germany, Bayer and DuPont are building on their
position as leading manufacturers of engineering thermoplastics.
With an initial capacity of 80,000 tons per year, the plant is the biggest of its
kind in the world. It will be operated by DuBay Polymer
GmbH, a joint venture between Bayer and DuPont. The two companies have together
invested some 50 million euros in the plant, in which 61 people
are employed.
For a company to
thrive in today's highly competitive market, it must be able to
supply top-quality PBT at competitive prices. In Europe, this is
only possible with large world-scale plants and state-of-the-art
production technology. "Neither of the two companies, DuPont
or Bayer, can make adequate use of such a plant immediately on
their own, despite the favorable growth forecasts," said Dr.
Hagen Noerenberg, head of Bayer Polymers, at the dedication
ceremony. "With the jointly operated facility, both partners
will strengthen their positions in the keenly contested global
market for PBT," said Ferdinand Bauerdick, DuPont´s
Director Europe Engineering Polymers, who is also responsible for
the global polyester business of DuPont. Both companies use the
straight resin from the production facility and compound it into
products for their PBT ranges ー Crastin® in the case of DuPont, and Pocan® in
Bayer's case.
In 2002, some
140,000 tons of the polymer were processed in Europe. Global
demand for PBT will grow in the next few years at an
above-average rate of somewhere between six and eight percent a
year.
One of the strengths
of PBT is its broad, well-balanced property profile. The
high-tech plastic is noted among other things for its good heat
and chemical resistance, its high stiffness and its ease of
processing. It also has outstanding electrical insulating
properties, produces parts with an excellent surface finish and
can be readily combined with other plastics to produce blends.
The material has a
particularly promising future in the automotive and
electrical/electronic industries. These two segments are the main
customers for PBT, accounting together for around 80 percent in
more or less equal shares. Products for medical, sport and
leisure applications are also made from this high-performance
plastic.
The new production
plant at DuPont's Hamm-Uentrop site is integrated entirely into
the infrastructure of the Chemical Parkー from the energy supply to the
traffic links and raw material logistics. The new PBT plant,
which was built in just under two years, also sets new standards
in terms of environmental protection and occupational safety. For
example, no solvents are used to manufacture the plastic, and the
only by-product, methanol, is fed back completely into the
production process. "Virtually 100 percent of the raw
materials go into the desired product. In this way, we conserve
valuable resources," said Dr. Hubert Fink, chairman of the
members committee of DuBay Polymer GmbH.
March 22, 2004 Bayer
CropScience
Bayer CropScience to purchase Crompton's share of Gustafson seed
treatment business
Acquisition for 124 million US Dollar in North America and Mexico
http://www.bayercropscience.com/bayer/cropscience/cscms.nsf/id/D50F9538CF30D718C1256E5F0052372E?Open&ccm=400190000&L=EN&markedcolor=%23003399
Bayer CropScience LP in
the U.S. and Bayer CropScience Inc. in Canada today signed
agreements to purchase Crompton Corporation's 50 percent share of
the Gustafson seed treatment business in the United States,
Canada and Mexico [NAFTA] for the purchase price of U.S.$124
million in cash.
The action would give Bayer CropScience, which already holds a 50
percent share of the U.S. and Canadian Gustafson joint ventures, full ownership of
Gustafson's NAFTA business, subject to customary closing conditions.
The transaction is expected to close by the end of the first
quarter.
Gustafson manufactures and markets seed treatment products and
related equipment. Based in Plano, Texas, and Calgary, Canada,
the company employs approximately
250 people in the NAFTA region. In 2003, Gustafson sales were
approximately U.S.$130 million.
“Purchase of the Gustafson seed treatment
business would allow us to participate directly in this
increasingly important segment of the NAFTA crop protection
markets,” said Emil Lansu, President & CEO of
Bayer CropScience LP and head of Bayer CropScience for the NAFTA
region. According to Lansu, the acquisition would give Bayer
CropScience the benefit of the full range of Gustafson’s
products, including certain products from third parties, which
would continue to make up a key component of the Gustafson
product portfolio. “We presently have several strong seed
treatment products,” Lansu added. “With the
Gustafson purchase we look to more fully realize the potential of
this business while enhancing our ability to provide solutions
for growers.”
Crompton
Corporation, with annual sales of $2.2 billion, is a producer and
marketer of specialty chemicals and polymer products and
equipment. Additional information concerning Crompton Corporation
is available at www.cromptoncorp.com.
Bayer CropScience, a subsidiary of Bayer AG with annual sales of
about EUR 5.8 billion (2003), is one of the world’s
leading innovative crop science companies in the areas of crop
protection, non-agricultural pest control, seeds and plant
biotechnology. The company offers an outstanding range of
products and extensive service backup for modern, sustainable
agriculture and for non-agricultural applications. Bayer
CropScience has a global workforce of about 19,000 and is
represented in more than 120 countries, ensuring proximity to
dealers and consumers.
May 4, 2004 Bayer
Agreement signed to build a plant for the coating raw material
HDI
Bayer: Investments to strengthen growth in China
http://www.news.bayer.com/News/News.nsf/id/2004-0258
In the presence of
Gerhard Schroder, the German Chancellor, and Wen Jiabao, the
Chinese Premier, Werner Wenning, the Chairman of the Board of
Management of Bayer AG, and Prof. Gottfried Plumpe, a member of
the Board of Management of Bayer MaterialScience AG, signed an
agreement with Ruan Yanhua, President of the Shanghai Chemical
Industry Park Corporation, to build a world-scale production
plant for the coating raw material HDI
(hexamethylene diisocyanate). The ceremony was held during the third
German-Chinese high-technology dialogue forum on May 4, 2004, in
Berlin.
The HDI project involves a total capacity of up to 50,000 t/y and an investment of some USD
100 million. Construction of the new facility is scheduled to
begin in fall 2004. HDI is a precursor for aliphatic
polyisocyanates, which serve as raw materials for high-grade
polyurethane coating systems. Such systems are used predominantly
for automotive, industrial and plastics coatings. Bayer is the
market and technology leader in this field.
"China is already one of our most important markets,"
said Management Board Chairman Wenning during the signing of the
agreement. "China's importance for the chemical and
pharmaceutical industry will increase further in the coming
years. Bayer wants to play a leading role in the economic
development of the People's Republic. With our investments in
Caojing, we are creating ideal conditions for strengthening our
growth in this key market."
Over the next few years, total investments of some USD 3.1
billion are scheduled for the integrated production site at
Caojing near Shanghai. Of this, Bayer will spend some USD 1.8
billion on new facilities for polymer production - construction
work has already begun in some cases. Other projects worth a
total of USD 1.3 billion are also planned, but these will be
tackled later.
With the building of large capacities for polyisocyanates,
Caojing will become the main production site for Bayer
MaterialScience's coating raw materials in the Asia-Pacific
Region. Initial production capacity for the precursor HDI will
reach 30,000 t/y by 2006. Depending on the way the market
develops in the region, capacity could be extended by a further
20,000 t/y as part of a second construction phase. Since April
2003, coating raw materials in the Desmodur® N range have been produced in a
neighboring plant that has an annual capacity of 11,500 t. At the
end of 2004, a production facility for Desmodur® L with a capacity of 11,000 t/y is also
due to go on stream.
Also at the Caojing site, construction has started on a new
world-scale production plant for Makrolon® polycarbonate. The intention is that the
plant will go on stream in 2006, and will gradually be expanded
to reach a total capacity of 200,000 t/y - in line with market
developments. A further focus of investment is the construction
of world-scale production facilities for the two polyurethane raw
materials, MDI and TDI, which are used predominantly in the
manufacture of polyurethane foams. The plants for MDI and TDI are
scheduled to begin production by 2008 and 2009 respectively.
With sales of around EUR 1.1 billion in 2003, the Greater China
country group is Bayer's second-largest single market in Asia
after Japan. The company employs more than 2,700 people in
Greater China and is also represented there by a total of 24
firms. Eleven manufacturing companies from all Bayer's areas of
business are now producing in the region, with the result that an
increasing proportion of sales is being covered by local
production.
July 19, 2004 Bayer
Bayer to Acquire Roche Consumer Health
http://www.news.bayer.com/News/News.nsf/id/2004-0448
Acquisition creates global
consumer health care company that will rank among top three
worldwide / Acquisition price EUR 2.380 billion including U.S. joint
venture
With the acquisition of Roche Consumer Health, Bayer is going to
extend its portfolio of long-standing brands for commercial
success.
Bayer announced today that it has agreed to acquire Roche
Consumer Health. By acquiring this business Bayer will become one
of the top three over-the-counter (OTC) consumer health companies
worldwide. Additionally, Bayer will acquire Roche's 50 percent
share of the 1997 Bayer/Roche joint venture in the U.S., (an element not included in Roche's
original offering) and five Roche production sites in Grenzach
(Germany), Gaillard (France), Pilar (Argentina), Casablanca
(Morocco) and Jakarta (Indonesia). The OTC business of the Japanese company
Chugai, in which Roche has a majority stake, is not included. The acquired business has yearly sales of
around EUR 1 billion. The EUR 2.380 billion transaction is
subject to approval by relevant antitrust authorities.
“It is our intention to
further strengthen Bayer’s
OTC business to become world leader, and with this acquisition we
make another large step towards this goal,” said Werner Wenning, Chairman of the Board
of Management of Bayer AG. “By
combining the two businesses we can realize significant
synergies. Additionally, the acquired business is of high value -
the combined product portfolios are very complementary and
contain strong trusted brands. The acquisition also provides
growth and attractive profit margins in an interesting and fast
developing part of the health care market -- one which is
characterized by increasing consumer interest in overall health
and self-medication. This is a good opportunity for our products.”
Bayer HealthCare's Consumer Care
Division and Roche Consumer Health share a heritage of building
on their long-standing brands for commercial success. Both have a
number of significant analgesic, dermatological, gastrointestinal
and nutritional brands that offer outstanding growth potential
across the globe. Combined brand equities include such well-known
brands as Bayer's Aspirin®, Alka-Seltzer®, Midol® and One-A-Day® and Roche's Aleve®, Bepanthen®, Berocca®, Flanax®, Redoxon®, Rennie®, and Supradyn®.
Both companies have a strong market presence in Europe and the
Americas and the move also builds greater presence for Bayer
HealthCare in the growing Asia-Pacific region. “Through this acquisition we intend to
leverage the capabilities, reputation, and strong brands of both
companies to create a world leading OTC company,” said Arthur Higgins, chairman of the
Executive Committee of Bayer HealthCare. “The new organization will be uniquely
positioned to exploit the growth potential in the OTC-market and
emerge as a partner of choice for future Rx/OTC-switches.”
Assuming approval from the relevant
antitrust authorities and subsequent closing of the transaction
by the turn of the year 2004/2005, after one time charges of
about EUR 300 million Bayer expects an EPS impact (earnings per
share) of 0.25 EURO /share in 2005 and a positive impact on
results from 2006 forward. The synergy potential is estimated at
approximately EUR 100-120 million. It is planned to realize the
synergy potential gradually over the next three years.
Bayer plans to finance the acquisition out of existing
facilities. Bayer had liquid assets of EUR 2.6 billion at the end
of the first quarter 2004 and thus a sound basis for financing
the transaction.
The combined company will have sales of EUR 2.4 billion and 6,700
employees in 120 countries. It will be headed by Gary Balkema,
currently president of Bayer HealthCare’s global Consumer Care Division and have
its global headquarters in Morristown, New Jersey, U.S.A. Mr.
Balkema is an experienced Consumer Care executive who has
successfully enabled Bayer’s
consumer health business to consistently outperform the OTC
market for the past five years. The European headquarters will be
in Switzerland in the Basel area. Research and development for
the new organization will be situated at Bayer Consumer Care
headquarters in Morristown and at the Roche Consumer Health site
in Gaillard, France.
About Bayer
Bayer is a research-based, growth-oriented global enterprise with
core competencies in health care, nutrition and high-tech
materials. In 2003, Bayer employed some 115,400 people and had
sales of EUR 28.6 billion. The capital expenditure budget for the
current year is EUR 1.8 billion, the R&D budget EUR 2.3
billion. The Bayer Group is committed to the principles of
sustainable development ? with economic growth, ecological
integrity and social responsibility accorded equal priority in
its corporate activities throughout the world. For more
information on Bayer go to www.bayer.com.
About Bayer HealthCare
Bayer HealthCare, a subgroup of Bayer AG with sales of
approximately EUR 8.9 billion in 2003, is one of the world's
leading, innovative companies in the health care and medical
products industry.
The company combines the global activities of the divisions
Animal Health, Biological Products, Consumer Care, Diagnostics
Professional Testing Systems and Diagnostics Self Testing Systems
and Pharmaceuticals. 34,600 people are employed by Bayer
HealthCare worldwide. Bayer Consumer Care, a division of Bayer
HealthCare, is headquartered in Morristown, N.J. Bayer Consumer
Care is among the largest marketers of over-the-counter
medications and nutritional supplements in the world. Some of the
most trusted and recognizable brands in the world today come from
the Bayer portfolio of products. For more information on Bayer
HealthCare, go to www.bayerhealthcare.com.
About Roche
Headquartered in Basel, Switzerland, Roche is one of the world’s leading innovation-driven healthcare
groups. Its core businesses are pharmaceuticals and diagnostics.
Roche is number one in the global diagnostics market and is the
leading supplier of pharmaceuticals for cancer and a leader in
virology and transplantation. As a supplier of products and
services for the prevention, diagnosis and treatment of disease,
the Group contributes on a broad range of fronts to improving
people’s health and quality
of life. Roche employs roughly 65,000 people in 150 countries.
The Group has alliances and research and development agreements
with numerous partners, including majority ownership interests in
Genentech and Chugai.
Alka-Seltzer, Aspirin, Midol and One-A-Day are registered
trademarks of Bayer AG.
Aleve, Berocca, Flanax, Redoxon, Rennie and Supradyn are
registered trademarks of F. Hoffman-LaRoche Ltd.
Roche and Bayer to form an OTC
joint venture in the United States
http://www.roche.com/media-news-1996-09-16-e.pdf
Roche Holding Ltd., Basel,
Switzerland and the US subsidiary of Bayer AG, Leverkusen,
Germany, have entered into a letter of intent to form a 50-50
joint venture to market several over-the-counter (OTC) drugs in
the United States.
Subject to the approval of the relevant authorities, the joint
venture will combine the companies' US OTC businesses in
analgesics (except for Bayer Aspirin) and women's health. Brands
included in the joint venture will be Roche's Aleve analgesic and
Femstat 3 vaginal yeast infection treatment and Bayer's Actron
and Vanquish analgesics, Midol menstrual pain reliever and
Mycelex-7 vaginal yeast infection treatment.
Bayer will be responsible for sales and marketing of the joint
venture products within its overall Consumer Care portfolio.
Financial terms of the agreement were not disclosed.
In addition to Bayer Aspirin, the joint venture will not include
other leading Bayer brands such as Alka-Seltzer, Alka-Seltzer
Plus and One-A-Day and Flintstones vitamins.
Anthony J. Jamison, head of Roche Consumer Health, Roche's
worldwide selfmedication business, said the agreement with Bayer
is "an excellent opportunity for Roche to build on the
success already gained with Aleve and Femstat-3 in the United
States and to develop a substantial OTC presence in the US
market. We are very pleased to join forces with a strong partner
in those segments of the OTC market where Roche has leading
products.”
"With this joint venture, we
will further strengthen Bayer's presence in the US OTC
marketplace,” said Werner
Spinner, head of Bayer's worldwide Consumer Care Business Group.
"Bayer will now be a contender for third place among the
nation's largest OTC health care marketers and will compete even
more significantly in the US OTC analgesic market.”
A committee with an equal number of
members from each company will exercise joint effective control
of the venture. Operational management will be contracted by the
joint venture to Bayer Corporation Consumer Care Division, based
in Morris Township, New Jersey.
This new agreement follows the June 1996 acquisition by Roche of
Procter & Gamble's 50 percent stake in a 50:50 joint venture.
In this agreement, Procter & Gamble had marketed Roche's
Aleve and Femstat 3 brands in the United States.
With the new joint venture, marketing and distribution services
will be transferred from Procter & Gamble to Bayer, with
Procter & Gamble maintaining responsibility for professional
selling until the end of 1997. "This process will be
non-disruptive and transparent to our trade and retail
customers," explained Werner Spinner. "We will begin
working immediately to ensure a smooth transition and expect the
transfer to be completed by the end of the year."
2004/09/13 Bayer
バイエル社とシェリング・プラウ社、医療用医薬品事業で戦略的業務提携に合意
http://release.nikkei.co.jp/detail.cfm?relID=81176
■米国と日本でマーケティング・販売の業務提携を締結
■米国の医療用医薬品事業のポジショニングを修正
■がん領域における世界的な事業部を設立
バイエル社は、同社ヘルスケア事業（バイエルヘルスケア社）の組織的再編を引き続き行い、米国に本拠を置くシェリング・プラウ社（本社：ニュージャージー州ケニルワース）と医療用医薬品事業に関する広範な業務提携を締結したことを本日発表しました。この合意内容に基づき、米国でのバイエル社のプライマリーケア製品（主にかかりつけ医で最初の治療として処方される薬剤）は、シェリング・プラウ社がマーケティングおよび販売を行ないます。
また両社は、日本におけるシェリング・プラウ社の循環器系疾患治療薬ゼチア（Ｒ）の将来的な共同販売についても合意しました。さらに、バイエル ヘルスケア社の医療用医薬品事業部は、米国を拠点としたがん領域のグローバル事業部を新たに設立し、米国の同社組織を高収益で専門性の高い製品とバイオテクノロジー製品に特化するよう方向転換させます。
バイエル社経営委員会代表ヴェルナー・ヴェニングは次のように述べています。
「一般消費者向けビジネスでの拡大を狙ったロシュ社の一般用医薬品事業買収に続き、バイエル ヘルスケア社は新たな戦略的節目を迎えました。シェリング・プラウ社との提携により、両社はお互いが得意とする地域での強みを生かすことができます。本提携により、米国におけるバイエルのコスト構造とリソースを調整して戦略的業績目標達成を可能にし、当社製品の潜在的可能性を更に引き出すことができます。同時に、日本での事業拡大を推進します」。
この合意内容に基づき、シェリング・プラウ社は米国およびプエルトリコにおけるバイエル社のプライマリーケア製品のマーケティングおよび販売を担当し、米国におけるバイエル社のマーケティングおよび販売組織の大部分はシェリング・プラウ社に統合されます。シェリング・プラウ社の増強された営業組織による情報提供活動は、季節的な活動量の変動にも柔軟に対応することが可能で、バイエル製品のポテンシャルを大きく引き出します。バイエル社では、米国での同社プライマリーケア製品のマーケティング・販売に携わる約１，８００人の社員が、シェリング・プラウ社への移籍、または組織縮小によって影響を受けると見ています。
バイエル社の製品は、引き続きバイエル社がその所有権および法的責任を保有し、バイエルのブランド名で販売されます。本契約は既存製品だけに適用され、開発中の製品は含みません。
シェリング・プラウ社はバイエル社の抗菌剤アベロックス（Ｒ）とシプロ（Ｒ）、循環器系疾患治療薬アダラート（Ｒ）、そしてその他のプライマリーケア向け製品を米国およびプエルトリコで販売することになります。シェリング・プラウ社は、これらの製品の実質売上に応じたロイヤルティーをバイエル社に支払います。またシェリング・プラウ社は、バイエルヘルスケア社とグラクソ・スミスクライン社（ＧＳＫ）が共同販売契約を結んでいるレビトラ（Ｒ）についても、米国での販売責任を担います。シェリング・プラウ社とバイエル社は米国におけるレビトラの販売利益のうちバイエル社に分配される分を分け合います。その他にもシェリング・プラウ社が米国およびプエルトリコにおいて販売する製品として、アレルギー・呼吸器疾患治療薬ナゾネックス（Ｒ）、クラリネックス（Ｒ）、フォラジール（Ｒ）、および循環器系疾患治療薬バイトリン（Ｒ）、ゼチア（Ｒ）があります。
この発表と同時に、バイエル社は世界市場を担うがん領域の事業部を新たに設立し、その営業組織を構築します。このがん領域事業部はコネチカット州ウエスト・ヘブンに本部を置き、オニックスファーマシューティカル社と共同開発中の抗がん剤ＢＡＹ ４３−９００６の承認取得および発売の準備を行います。進行性腎細胞がんの治療薬として臨床試験で有望な結果を示しているこの開発候補品は、現在第ＩＩＩ相臨床試験が行われています（日本国内では第Ｉ相臨床試験）。今回の契約に基づき、バイエル社は米国および欧州の主要な市場でシェリング・プラウ社のがん領域製品の販売活動を一定期間行ないます。前立腺がん治療に使われるバイエルのヴィアデュール（Ｒ）もこのがん領域事業部で取り扱います。
バイエル ヘルスケア社経営委員会代表のアーサー・ヒギンズは次のように述べています。「シェリング・プラウ社との提携は、重要な米国市場における私たちのプライマリーケア製品群の業績を高め、バイエル社医療用医薬品事業にコスト構造と利益率の改善をもたらします。また、がん領域のグローバル事業部を設立し、この重要な治療分野での基盤を築くなど、医療用医薬品事業の将来への投資能力を向上させることができます。」
日本では、シェリング・プラウ社の新規コレステロール吸収阻害剤ゼチア（Ｒ）（現在、申請中）の共同販売契約が含まれています。バイエル社の日本法人であるバイエル薬品は、循環器系疾患領域において長年にわたる経験があり、その強みを活かすことによって同製品の上市をサポートします。
バイエル ヘルスケア社、米国医療用医薬品事業部でプライマリーケア以外の組織は、これまで同様ウエスト・ヘブンを本部とし、主に専門医が扱う高収益な専門領域の製品とバイオテクノロジー製品に集中します。がん領域の製品に加え、血友病治療薬コージネイト（Ｒ）と、開胸心臓外科手術で使われるトラジロール（Ｒ）が、その製品ポートフォリオです。
本契約は、２００４年１０月１日に効力が生じ、速やかに実行に移される予定です。この組織縮小と臨時的な一時経費のため、バイエル社は５，０００万から７，０００万ユーロの特別費用を計上する見込みで、その大半は２００４年度中に発生します。本契約は、翌年以降から収益に貢献すると予想しています。
■ドイツ・バイエル社について
バイエル（http://www.bayer.com）は研究開発を基盤とする成長志向のグローバル企業であり、今後、ヘルスケア、農薬関連、先端素材の３つの領域において中核事業に専念していく方針です。これにともない、既存の化学品事業と高分子材料事業の一部を新会社「ＬＡＮＸＥＳＳ」に移管し、２００５年初頭までに株式市場への新規上場を予定しています。バイエルグループは「持続的な発展」を企業理念に掲げ、経済成長、環境保全、企業の社会的責任において調和のとれた活動をグローバルに展開しています。全世界の従業員数は１１５，４００人（２００３年末）。２００３年の売上は２８６億ユーロ。設備投資には１７億ユーロ、研究開発には２４億ユーロを投入しました。
■バイエル ヘルスケア社について
ドイツ・バイエル社の事業グループであるバイエル ヘルスケア社の年商は約８９億ユーロに達し、ヘルスケア、医療製品業界における世界の主要企業の一つです。バイエルヘルスケア社は、バイエル社の関連事業（動物用薬品、バイオロジカル プロダクト、コンシューマーケア、診断薬、医療用医薬品）の世界規模の活動を統括しており、世界中で３万４，６００人以上の従業員によって支えられています。全世界の人類と動物の健康を向上させるため、革新的な製品を開発・製造することがバイエルヘルスケアの使命です。私達の製品は、疾患の診断、予防そして治療を通じて、健康とＱＯＬ（クオリティ・オブ・ライフ）の向上に貢献します。
2004/12/13 バイエル
バイエル社、血漿分画製剤事業を米国投資会社
Cerberus社とAmpersand社に売却
http://release.nikkei.co.jp/detail.cfm?relID=88770&lindID=4
−コージネイト®は、バイエル ヘルスケア社の製品として継続販売−
「血漿分画製剤事業の売却は、バイエルヘルスケア社のビジネス再構築を進める上で重要なステップです。バイエル社はこれまで以上に、コンシューマー向けヘルスケア製品、人と動物向けの画期的医薬品と高性能診断機器のビジネスに注力します。バイエル社が行ったロシュ社一般用医薬品事業の買収とシェリング・プラウ社との医療用医薬品事業提携は、この新たな戦略的再編を強調するものです」とバイエル社社長ヴェルナー・ヴェニングは述べています。
本契約の内容には、バイエル ヘルスケア社バイオロジカルプロダクト事業部の血漿分画製剤事業に関連する製品、施設そして社員が含まれています。血友病Ａの治療に使用される遺伝子組換え型血液凝固第ＶＩＩＩ因子製剤コージネイト®は売却対象ではなく、バイエル ヘルスケア社の製品としてこれまでどおりに販売されます。
「コージネイトＦＳ®およびコージネイト®は、バイエル ヘルスケア社のポートフォリオの中で最も貴重で、戦略的にも重要な製品のひとつです。今後さらにビジネス再編を計る上で、この製品は長期戦略に不可欠で、それによって世界中の血友病市場でリーダーシップを発揮することができるのです」とバイエル ヘルスケア社経営委員会代表アーサー・ヒギンズ氏は述べています。
バイエル社血漿分画製剤の２００４年１月から９月までの売り上げは４億８１００万ユーロでした。主要製品には、免疫不全の治療に用いられるポリグロビン®／ガミュミューン®／ガミュネックス®、そして先天性肺気腫に用いられるプロラスチン®があります。本事業は、米国ノースカロライナ州リサーチトライアングルに本部を置き、米国では約１６００名の社員が勤務しています。
「非常に幅広い製品パイプライン、卓越した製造技術、病原体混入防止に向けた安全性研究、患者さんに対する強い責任感をもつ会社へ投資できることを大変うれしく思います。この戦略の一環として、NPS
Bio Therapeutics社は現在バイエル社へ血漿分画工程業務を提供しているPrecision
Pharma Services社を統合する予定です。現行の経営陣との連携の下、新しい経営組織は、NPS
Bio Therapeutics社の業界でのリーダーシップをさらに発揮していきます。医療従事者と患者団体へのより良いサポートを推進しながら、この事業を成長させ強化していきます」とCerberus社の統括メンバーで、NPS
BioTherapeutics社の会長に就任するラリー・スターン氏は述べています。
【 ドイツ・バイエル社について 】
バイエル（http://www.bayer.com）は研究開発を基盤とする成長志向のグローバル企業であり、今後、ヘルスケア、農薬関連、先端素材の３つの中核事業に専念していく方針です。これにともない、既存の化学品事業と高分子材料事業の一部を新会社「ＬＡＮＸＥＳＳ」に移管し、２００５年初頭までに株式市場への新規上場を予定しています。バイエルグループは「持続的な発展」を企業理念に掲げ、経済成長、環境保全、企業の社会的責任において調和のとれた活動をグローバルに展開しています。全世界の従業員数は１１５，４００人（２００３年末）。２００３年の売上は２８６億ユーロ。設備投資には１７億ユーロ、研究開発には２４億ユーロを投入しました。
【 バイエル ヘルスケア社について 】
ドイツ・バイエル社の事業グループであるバイエル ヘルスケア社の２００３年総売り上げは約８９億ユーロに達し、ヘルスケア、医療製品業界における世界の主要企業の一つです。バイエルヘルスケア社は、バイエル社の関連事業（動物用薬品、バイオロジカル プロダクト、コンシューマーケア、ダイアベティスケア、診断薬、医療用医薬品）の世界規模の活動を統括しており、世界中で３万４，０００人以上の従業員によって支えられています。全世界の人類と動物の健康を向上させるため、革新的な製品を開発・製造することがバイエルヘルスケアの使命です。私達の製品は、疾患の診断、予防そして治療を通じて、健康とＱＯＬ（クオリティ・オブ・ライフ）の向上に貢献します。
【 Cerberus Capital Management, L. P.社について 】
Cerberus Capital Management, L. P.社は、ニューヨークに拠点を置く１９９２年創立の民間投資会社で、１４０億ドル超える投資資産を管理しています。Ｃｅｒｂｅｒｕｓ社は、北米、欧州、アジアでの事業を含む、様々なビジネス分野において４０社以上の経営権を保有しています。Ｃｅｒｂｅｒｕｓ社は、資産価値を重視する投資会社で、長期に渡る高収益力の業績を求め、自社とのパートナーシップによる収益性を追求します。
【 Ampersand Ventures社について 】
Ampersand Ventures社は、Panie Webber社から分離した１９８８年創立の民間の株式投資会社で、積極的な事業提携を通じて資産価値の増やすことに注力しています。Ａｍｐｅｒｓａｎｄ社は、広範囲の技術産業の分野に渡って独自の投資戦略を追求します。会社の資産の大半は、売却会社、拡大融資、中規模の企業買収そして業績回復のための資本再構成のポートフォリオに投資されます。Ampersand社は、１９９５年から血液製剤事業積極的な投資を行っており、現在バイエル社へ血漿分画工程業務を行っているPrecision
Pharma Services社の経営権を保有しています。
Miles' switch to Bayer
adds to global identity
http://waw.wardsauto.com/ar/auto_miles_switch_bayer/
Keenan, Tim
Customers and
employees of Bayer Corp. - formerly Miles and once Mobay - may
need to take a couple of the company's aspirin tablets now that
it has changed its name for the second time in a little more than
three years.
The latest revision
of the Pittsburgh, PA-based plastics supplier's nomenclature will
give the company one worldwide name and a stronger position as
the auto industry progresses toward globalization, says H. Lee
Noble, president of Bayer's polymers division.
The Miles-to-Bayer
switch comes five months after Miles acquires Sterling Withrop's
North American over-the-counter drug business, including Bayer
aspirin and the Bayer trademark. Mobay-Miles Miles always had been a
subsidiary of Bayer AG, the German-based international chemical
and health care company.
"Until we
acquired the Bayer aspirin business we could not use the name in
the U.S.," explains Mr. Noble, who adds that the company was
known as Miles only in the U.S. and Canada."
Now Mr. Noble again
must establish an identity for a new name. In January 1992 the company, which had been
called Mobay since it was established in 1954, changed its name
to Miles. He admits
the frequent changes have caused a bit of confusion among
customers, but believes this transition will be easier.
"There was some
confusion for a while when we changed the name to Miles,"
Mr. Noble recalls. "We had the Mobay name pretty
recognizable." He says it took about a year to get everyone
acclimated to the new name then. That move was made because Miles
had better global recognition at the time than Mobay.
"This change
will be accepted more quickly in the auto industry because of the
Big Three's "connections to the European industry,"
says Mr. Noble. "Globally, Bayer is an automotive name. Most
of Detroit has recognized for years that we are a subsidiary of
Bayer in Germany."
Bayer supplies raw
materials for many automotive components including seat cushions,
bumpers, interior pieces and exterior coatings. The company
claims it's the world's largest supplier of polyurethane.
With the new name,
Mr. Noble says the company will have a renewed global orientation
"It's something you really have to work at," he says of
the industry's globalization trend, which Bayer anticipated 15
years ago when it instituted its World Automotive Committee.
"It takes a real effort to get that coordination, preventing
working at cross purposes," he adds.
Mr. Noble says he's
not concerned about the industry's recent slowdown. hi fact, he's
excited about Bayer's potential to pounce on several industry
growth opportunities.
"But even if
(the market) does slow down more than we expect, our products are
still taking a greater share of the materials market," he
says. "The value of plastics will continue to grow."
Body panels,
interiors, side-impact energy absorption and recycling are the
most fertile ground for plastics industry growth, says Mr. Noble.
"We recognize
the importance of recycling to the auto industry and have focused
our research and development efforts on solving this
challenge," he says.
Fruits of these
efforts include a proprietary technology allowing polyurethane
RIM scrap to be molded into new parts. The 1994 Jeep Renegade
features a close-out panel molded completely of recycled RIM
polyurethane. The part was compression molded from RIM scrap from
Chrysler minivans and replaced a part originally made from new
material.
Bayer believes the
100% recycle-content material will see future uses in fender
liners, wheel-well liners, air ducts, air deflectors and other
parts requiring strength but not a high-gloss surface.
The company's other
primary recycling initiative is a process to recycle seat-cushion
foam.
バイエル、日本において市場成長率を上回る発展に注力
−2005年1-9月期の売上は7.8%増の1,490億円
−2008年までに1億3,000万ユーロ以上を投資
http://www.bayer.co.jp/bgj/newsfile/news/news-248_j.html
「日本におけるドイツ年2005/2006」に積極貢献
バイエルグループ（本社：ドイツレバクーゼン、代表取締役社長：ヴェルナー・ヴェニング）は、日本においてさらなる発展を目指しており、2008年までに1億3,000万ユーロ以上を日本に投資する計画である。「日本におけるドイツ2005/2006」の一環として開催されたバイエル主催のイベント週間「バイエルウイーク」中に東京で行われた記者会見の席上、ヴェルナー・ヴェニングは次のように述べた。「バイエルにとって日本はアジア太平洋地域最大の市場であり、また最も成功した市場です」2005年1-9月期の日本のバイエルグループの売上高は前年同期比7.8%増の1,490億円であった。日本はバイエルにとって、米国、ドイツに次ぐ第3位の市場となる。「バイエルは、日本でさらにプレゼンスを拡大し、市場成長を上回る発展を達成するという強い意志があります」とヴェニングは語った。
「日本では、すでに全ての事業グループが極めて強固な基盤を確立しています」とヴェニングは 続けた。グループ総売上のうち最大の割合を占めるのは、ヘルスケア事業グループ（バイエルヘルスケア）であり、2005年1-9月期の同事業グループの売上は前年同期比5.6%増の730億円を計上した。これは日本のバイエルの売上のほぼ半分に相当する。ヘルスケア事業で最大の割合を占める医療用医薬品事業は、厳しい市況にもかかわらず、安定した成長となった。特に「アダラート(R)」、「グルコバイ(R)」、「バイアスピリン(R)」をはじめとする脳・心血管系リスクマネジメント製品が好調であった。ヘルスケア事業のダイアベティスケア、診断薬、動物用薬品も2005年1-9月期にそれぞれ27％、11％、17％という優れた成長率を達成した。
ヴェニングはバイエルの展望に明るい見通しを立てており、「日本において、ヘルスケア部門は成長を遂げており、今後も市場成長率を上回る成長を達成できると確信しています」と述べた。10月には、広範な抗菌スペクトルを有すニューキノロン系抗菌剤「アベロックス(R)」の輸入販売承認を得た。呼吸器感染症のプライマリーケアに使用できる本製品の販売を行う塩野義製薬（株）は、年内の上市を見込んでいる。日本の経口抗生物質市場は、2004年現在で年商 約20億ユーロの規模を持つ。
ヘルスケア事業をさらに強化する計画として、米国シェリング・プラウ社が開発したコレステロール吸収阻害剤「ゼチア
(R)」を、日本の当局の承認後発売する予定である。シェリング・プラウ社とバイエル薬品との間で、日本における同製品の共同販売契約がすでに 締結されている。また、バイエルが開発中の製品には、例えば、新たな抗がん剤「ネクサバール(R)」、血栓症治療を目的とした経口直接作用型Xa因子阻害剤など非常に有望な製品が含まれているとヴェニングは説明した。
農薬関連事業グループ（バイエルクロップサイエンス）の売上は260億円で、前年同期に比べて減少した。これは主に複数の製品の売却が原因である。しかし、コスト管理の強化により純利益は増加した。今後5年間に農薬関連事業グループは7つの有効成分を日本市場に導入する計画である。
素材科学事業グループ（バイエルマテリアルサイエンス）は、2005年1-9月期において前年 同期比24.7％増という大幅な成長を達成し、売上は500億円となった。ポリカーボネートおよびポリウレタン市場、特にハイテク樹脂「マクロロン(R)」や硬質フォーム用原料MDIの市場において強い需要が見られ、その結果、原料費の高騰を背景に製品価格が上昇し、満足すべき事業展開となった。ヴェニングは、特に「マクロロン(R)」、塗料原料、発泡素材が今後も成長すると予測している。
「バイエルには日本市場において長い成功の歴史があります」とヴェニングは強調した。バイエルが 日本で最初に事業を行ったのは1886年であり、1911年にはすでに最初の100％子会社を設立。2004年には日本で約2,500人の従業員を雇用し、14億4,900万ユーロの売上を達成した。バイエルは、ヘルスケア、農薬関連そして先端素材の分野において、全ての製品ポートフォリオを日本市場に提供している。技術革新はバイエルグループの最大の強みのひとつである。1990年以来、バイエルは約9億ユーロの研究費を日本に投じてきた。
さらに、ヴェニングはアジア太平洋地域の重要性を強調した。2003年には主に為替差損の影響で若干の低迷が見られたが、過去14年間の同地域におけるバイエルの業績は、力強い長期的な成長の可能性がこの地域にあることを示している。アジア太平洋地域におけるバイエルグループの売上（ランクセス社を含む）は、1990年から2004年の期間において、同グループの世界平均を2倍以上上回る年平均5.2％のペースで増加してきた。
「バイエルは、アジア太平洋地域に非常に強い関心を抱いており、この地域がここ10年間の資本投資の焦点になります」とヴェニングは指摘する。1990年から2004年にかけて、アジア太平洋地域におけるバイエルグループの設備投資と研究開発費の総額は29億ユーロに及ぶ。バイエルは、より一層の成長を促進するために、この地域にさらに資源を投入する計画である。
2005年1-9月期において、すでに約1,400人の従業員が新規に採用されている。これは他の地域を上回る実績である。
しかし、バイエルの現在の投資計画の中心を占めるのは中国である。バイエルは上海近郊のCaojing（カオジン）において、「マクロロン(R)」とポリウレタン原料の生産施設を中心に、2009年までに18億米ドルを投資する計画である。日本においては、世界第2位の医薬品市場であり、アジア最大の農薬市場であるために、ヘルスケアおよび農薬関連事業における革新的な 製品パイプラインの強化に重点を置く。ヴェニングは「バイエルは、グループ全体の売上高に占めるアジア太平洋地域の売上比率を2010年までに現在の17％から25％に引上げることを目指しています」と述べた。
バイエル、上海近郊の新生産基地に関する基本契約に調印
中国に31億ドルを投資
http://www.bayer.co.jp/bgj/newsfile/news/back-108_j.html
世界的なヘルスケア・化学グループであるバイエル（本社：ドイツ・レバクーゼン）は、中国における事業拡大のため、このほど中国・ソウケイ（Caojing）（上海近郊）の新生産基地に関する基本契約に調印した。総投資額は31億ドル（34億ユーロ）。ドイツ・バイエル社のCEOであるマンフレッド・シュナイダー社長は北京で、「世界市場で成功するには、一方では効率的な生産ネットワーク、もう一方では不可欠なクリティカル・マス（臨界量）が重要な要素になる。バイエルのソウケイ（Caojing）工場はその両方において大きな役割を果たすだろう。
このプロジェクトはアジアにおけるバイエルの大きな目標を達成するためのカギである」と述べた。
2001年10月31日、バイエルは中国・北京の人民大会堂でソウケイ（Caojing）の上海化学工業団地社との契約に調印した。式典には中国の朱鎔基首相、ドイツのシュレーダー首相、バイエルのシュナイダー社長が出席した。工場の着工は、2001年11月2日、中国・浦東のバイエルの新しい高分子研究センターの開所式と合わせて行われる。
シュナイダー社長によると、1994年に開始されたアジアへの投資計画の総額は2010年までに約60億ドル（70億ユーロ）に達する。バイエルは２０１０年までにグループ全体の売上に占めるアジアの比率を現在の16％から25％に引き上げる予定。
北京での記者会見で、シュナイダー社長は、「アジアは、米国の景気後退の結果、短期的に減速する可能性はあるが、引き続き長期的に高い潜在能力を示している。したがって、バイエルは同地域で事業を拡大するため、引き続きアジアに多額の資本を投資し、生産・製品開発施設を建設する」と述べた。
中国もバイエルのプロジェクトに関して特別な役割を担っていく。
中国のこの10年間の年平均成長率が17％ときわめて高く、バイエルの最も強力な成長市場の1つとなっている。バイエルは今後5年間に、売上を2000年水準の10億ドル（11億ユーロ）から少なくとも2倍以上に伸ばすことを目標としている。
ソウケイ（Caojing）での高分子材料の総合生産
今後のさらなる成長の基礎となるのは、上海化学工業団地の高分子材料総合生産基地の開発である。総投資額は31億ドル（34億ユーロ）。この野心的なプロジェクトは、いくつかの個々の生産施設を、インフラ、原料、ハイテクを共有するネットワークと結びつける。
上海工業団地社との契約の中心は、3つのコア・プロジェクト（塗料、熱可塑性樹脂、ポリウレタン原料の生産）の認可である。
各プロジェクトの概要
第１号プロジェクト
ソウケイ（Caojing）のバイエル新生産基地の第1号プロジェクトは、自動車、建設、家具業界で使用される塗料・着色材の製造である。バイエルは2008
年までに計1億1,000万ドル（1億2,200万ユーロ）を投資する。建設の第1段階では、ポリイソシアネートの生産施設（年産1万1,500トン）が建設される。操業開始は2003年の予定。その後、生産能力は年産2万トンに引き上げられる見込み。建設の第2段階では、原料となるHDIの生産ユニットも建設される。バイエルの100％子会社「バイエル塗料システムズ（上海）社」が2000年12月に事業免許を取得しており、このプロジェクトの運営にあたる。
第２号プロジェクト
ソウケイ（Caojing）の第2号プロジェクトは、バイエルのポリカーボネート「マクロロン」の世界規模の生産施設である。これは塗料生産施設と歩調を合わせて建設される。高機能ポリカーボネート「マクロロン」は、例えばCDやDVDなどの光学記憶システムに使用されるが、他にも電子、建設、自動車産業にも広範な用途がある。バイエルの合弁相手である上海クロルアルカリ社と協力して、バイエルは年産10万トンのポリカーボネート生産コンビナートを建設する予定である。
年産5万トンの生産能力を持つ当初の生産ラインが2003年に操業を開始し、2006年にはフル稼働する。当プロジェクトの総投資額は4億5,000万ドル（5億ユーロ）で、原料となるビスフェノールＡの生産施設と配合工場が含まれている。
このプロジェクトは、バイエルの新しい子会社「バイエル・ポリマー（上海）社」（バイエルが株式の90％、上海クロルアルカリ社が10％を保有）が運営にあたる。プロジェクトの事業免許は2001年9月に承認されている。
建設は2001年11月2日に開始する。
第３号プロジェクト
ソウケイ（Caojing）の第3の主要プロジェクトは、ポリウレタン原料の大規模生産施設である。多様な用途を持つポリウレタンは、軟質・硬質のフォームとして、特に家具、自動車、建設産業で多様な用途を有するほか、冷凍・冷蔵機器やスポーツ・娯楽産業の製品でも使用されている。
このプロジェクトは、バイエルの新しい100％子会社「バイエル・ポリウレタン（上海）社」の名称で運営される。総投資額は約11億ドル（12億ユーロ）で、年産38万トンのイソシアン酸塩工場が建設される。このうち
23万トンはMDI、15万トンはTDIである。ポリウレタン生産では、イソシアン酸塩に続いてポリオールが2番目に重要な生産品目である。ポリエーテルの生産量は年産28万トンの予定。
2001年8月、中国の国家発展計画委員会は、バイエルのポリウレタン生産施設の主要プロジェクトを承認した。バイエルは、2005年までに最初のポリウレタン工場の操業開始を目標としている。
追加プロジェクトの見通し
これらの3つの主要プロジェクトに加えて、追加のプロジェクト（複数）と土地借り入れの総投資額が14億ドル（15億5,000万ユーロ）に上るため、ソウケイ（Caojing）の総投資額は31億ドル（34億ユーロ）となる。プロジェクトには、高機能樹脂、その他の原料、基礎化学品の生産施設が含まれる。
上海化学工業団地の総面積は約24平方キロ。同工業団地はアジア最大の化学コンビナートになる予定で、総投資額は約200億ユーロの見込み。敷地は主として埋立地で、上海中心街の南50キロに位置しており、優れたインフラ、ロジスティクス、交通網を有している。
グレーター・チャイナ（中国、香港、台湾を含む）は、バイエルのアジア個別市場としては日本に続く第2の市場である。バイエルは投資の第1段階で、すべての事業分野に関わる中小生産会社12社を設立した。ソウケイ（Caojing）のプロジェクトは投資の第2段階の開始を反映しており、この第2段階は、中国およびアジア地域に供給を行う、世界規模の高分子材料生産施設の設立に焦点を当てている。
Bayer May 15, 2006
Bayer MaterialScience develops pioneering technology for the
production of TDI
http://www.baynews.bayer.de/BayNews/BayNews.nsf/id/2006-0267-e
High-output and resource-saving production process / Significantly reduced investment and operating costs / First use on a world scale at the integrated production site in Caojing
Bayer MaterialScience AG
has developed a pioneering technology for
producing toluene diisocyanate (TDI), which reduces the investment
costs involved in constructing production plants by 10 to 20
percent. Moreover, the technology reduces the energy consumption
by one third and sets new safety standards. A pilot plant with an
annual production capacity of 30,000 tons has been in operation
in the Bayer Chemical Park in Dormagen for over a year. The new
technology is scheduled to be used for the first time on a world
scale at Bayer MaterialScience’s Caojing site near Shanghai. The company plans
to construct a fully integrated TDI production plant there with
an annual capacity of 160,000 tons by the end of 2009. TDI is used
worldwide for the production of flexible polyurethane foam, large
quantities of which are used in upholstered furniture, mattresses
and automotive seating.
“The
new technology is a quantum leap in our development of
state-of-the-art production methods that offer even greater
efficiency. It provides an innovative system of energy management
and sets new standards in high-output, resource-saving production
methods,” says Peter Vanacker, head of the
Polyurethanes Business Unit at Bayer MaterialScience. “This enables us to support our
customers’ growth long-term by providing
top-quality products and to reinforce our leading role on the
global polyurethane market with optimum cost structures.
Following the success with the new technology, we will also
considering using it when constructing TDI plants in Europe in
the future.”
In the summer of
2005, Bayer MaterialScience finished years of work on a
consolidation process for TDI and its primary products and has
since focused its production on integrated world-scale plants.
The story is similar with methylene diphenyl diisocyanate (MDI),
an important raw material for producing rigid polyurethane foam,
which guarantees a highly efficient insulation effect. Bayer
MaterialScience is currently constructing a world-scale
production plant for MDI in Caojing with a capacity of
350,000 tons a year, which
is due to commence operation in 2008. The inauguration of a
splitter for recovering monomeric and polymeric MDI from crude
MDI is already scheduled for fall of this year. It will boast an
annual capacity of 80,000 tons.
With sales of EUR 10.7 billion in 2005, Bayer MaterialScience AG
is one of the world’s largest polymer manufacturers.
Its main fields of activity are the production of high-tech
polymer materials and the development of innovative solutions for
products used in many areas of everyday life. The main consumer
sectors are the automotive, electrical/electronics, construction,
sports and leisure industries. Bayer MaterialScience has
production facilities at 40 sites around the world and a
workforce of approx. 18,800. Bayer MaterialScience is part of the
Bayer Group.
September 5, 2006 Bayer
Bayer CEO Wenning at the inauguration of new production
facilities in Shanghai
“China
is of central importance to Bayer”
Total capital
expenditures of US$ 1.8 billion at the Shanghai Chemical Industry
Park through 2009
Significant capacity expansions for polycarbonates, polyurethanes
and coating raw materials
Bayer’s largest capital expenditure
project outside Germany
At a ceremony on Tuesday before 500 guests, Bayer inaugurated the
new production facilities of the Bayer MaterialScience subgroup
in Shanghai. “China is of central importance to
Bayer in the Asia-Pacific region ? both as a production base and
for our business strategy,” said Management Board Chairman
Werner Wenning, underlining the country’s significance for Bayer. The
project at the Shanghai Chemical Industry Park represents a total
capital expenditure volume of about US$ 1.8 billion through 2009,
explained Wenning in the presence of numerous guests from
politics, industry and the media: “This is our biggest-ever project
outside of Germany.”
At the inauguration
ceremony attended by leading representatives of the City of
Shanghai, the entire Management Board of Bayer AG and journalists
from Asia and Europe, Wenning said: “The integrated Bayer site in
Shanghai is developing into our biggest and most technically
advanced production site in the entire Asia-Pacific region. In
turn, this region ? and particularly China ? is one of the most
important future markets for the Bayer Group, a market that is
set to become even more significant and dynamic.”
Wenning said the
newly inaugurated facilities of Bayer MaterialScience will add
substantially to production capacities.
Bayer MaterialScience CEO Dr. Hagen Noerenberg described the
remarkable perspectives offered by the integrated site: “In the future this site will
supply customers throughout the region with approximately 900,000
tons of plastics products a year. Our long-term commitment to the
Chinese market and our customers here is a strategic cornerstone
of our activities. We aim to play a leading role in advancing the
Chinese plastics industry through our products, technologies and
employee training.”
In these respects
the company expects the new production facilities to play a key
role. Dr. Jurgen Dahmer - Senior Bayer Representative for Greater
China and Senior Representative for Bayer MaterialScience in
China, and thus “landlord”
of the Shanghai
site - presented the details of these plans in his welcoming
address. The existing facilities will now be supplemented by
- a world-scale polycarbonate production unit with
a starting capacity of 100,000 tons per year,
- the first polyurethane facility at the Bayer site - a crude MDI
(diphenylmethane diisocyanate) splitter with a capacity of 80,000
tons per year and
- a production unit for HDI (hexamethylene diisocyanate)
with an initial capacity of 30,000 tons per year.
The polycarbonate facility for the manufacture of Bayer’s high-tech material Makrolon(R)
represents a capital investment of US$ 450 million. There are
already plans to expand the capacity of this facility, which will
primarily supply customers in the region, to 200,000 tons per year by 2008. Makrolon(R) is
used in the manufacture of CDs, DVDs, automotive glazing and many
other applications. It is also used in the construction industry:
for example, the futuristic roof of the Tianjin Olympic Center
Stadium will be made of Makrolon polycarbonate. The company is
confident that the material will be used at other sports arenas
as well.
The Asia-Pacific region is the biggest market for polycarbonate
in terms of volume, with 1.5 million tons sold last
year, more than half the world market of 2.7 million tons. Of this volume, Greater China
alone accounts for 650,000 tons, with consumption growing at
around 18 percent a year.
Polyurethane raw materials are a further focus of production at
the site. These MDI-based intermediates are used in the
production of rigid foam for thermal insulation, among other
applications. The inaugurated facility - a “splitter”
that separates crude MDI into monomeric and polymeric MDI
- is just the beginning. A large-scale MDI production facility
with a capacity of 350,000 tons per year, due on stream in 2008,
will be the largest of its kind in the world. Also planned is a
production facility for the intermediate TDI (toluene diisocyanate), which is
used to manufacture flexible foams for applications such as car
seats, mattresses and furniture. With a capacity of 160,000 tons per year, this plant is expected
to come on stream in 2009.
Bayer began its production activities at the site in 2003 with
coating raw materials, for which capacity currently is 22,500
tons per year. The company will now be able to produce another 30,000 tons of
the raw material HDI,
with the option of expanding this capacity by a further 20,000
tons. Polyurethane-based coatings today offer the best
performance spectrum. They are used, for example, on the Lupu
Bridge - Shanghai’s most famous landmark - or in
high-tech automotive coatings to provide long-term protection
against weathering.
International news conference
At a news conference attended by journalists from around the
world, Wenning had already outlined the corporate context of the
investment projects in Shanghai. After explaining the Bayer Group’s overall strategic realignment,
Wenning emphasized the leading positions it holds worldwide in
the areas of health care, nutrition and high-tech materials.
Bayer had global sales of EUR 27.4 billion in 2005.
The strategic strengthening of the health care business through
the acquisition of Schering for approximately EUR 17 billion puts
Bayer in seventh position among suppliers of specialty
pharmaceuticals, Wenning commented. With Bayer CropScience the
world market leader in conventional crop protection and Bayer
MaterialScience the number one in polyurethanes and the number
two in polycarbonates, Bayer has a highly competitive portfolio,
he said. “This portfolio enables us to fully
capitalize on our value creation potential, particularly in the
Asia-Pacific region,” the Bayer Chairman explained.
Bayer has annual sales of EUR 4.6 billion in Asia-Pacific
Bayer’s sales in the Asia-Pacific region
climbed by 15.5 percent in 2005, to EUR 4.6 billion, which means
the region accounts for 17 percent of the Group’s business. The group has 55
subsidiaries and affiliates in the region, some 14,200 employees,
and last year served nearly every local market. Headcount has
since risen to about 18,000, including 2,900 Schering employees.
Thanks to high growth rates, the Greater China country group ?
which includes the People’s Republic of China, Hong Kong and
Taiwan ? already generates 28 percent of Bayer’s sales in the region, putting it
in second place behind Japan. The number of employees has jumped
from 3,700 to 4,900 over the past year, including about 600
Schering employees. It is planned to create more new jobs.
High growth rates for Bayer in China
Bayer’s sales in Greater China grew by
24 percent in 2005, to EUR 1.26 billion. According to Wenning,
this shows “that Bayer is participating in the
region’s dynamic economic growth. And
this positive trend is continuing: our sales here showed a 22
percent year-on-year gain in the first half of 2006, to EUR 714
million.”
Bayer
MaterialScience contributed by far the largest share of sales in
the first six months, with revenues of this subgroup advancing by
18 percent to EUR 524 million. BMS is targeting sales in excess
of EUR 1 billion for the year as a whole. The CropScience
subgroup raised sales by 33 percent, with Bayer HealthCare sales
growing even faster at 39 percent. The increase at HealthCare was
driven mainly by the Pharmaceuticals Division. Including the
Schering activities, Bayer ranks fifth among international
pharmaceutical suppliers in China.
“Bayer’s Solutions for China’s Needs”
Bayer plans to
invest US$ 26 million to enlarge HealthCare production facilities
in Beijing, Wenning announced. The company is thus making good on
the motto “Bayer’s Solutions for China’s Needs”, a regional variation on the
global slogan “Bayer: Science For A Better Life”. As an example of Bayer’s commitment to China, the
Management Board Chairman mentioned the diabetes initiative of
Bayer HealthCare. About 40 million Chinese already suffer from
diabetes, and this disease will affect an estimated 50 million
people there by 2008. In “diabetes houses,”
Bayer offers
patients improved access to diagnosis, treatment, monitoring and
consulting services. The medicine Glucobay to treat diabetes is
the top-selling product on the Chinese pharmaceuticals market,
Wenning said.
For 50 years, the Bayer CropScience subgroup has offered
innovative, high-quality products and solutions for local
agriculture needs in China. As part of the Agricare initiative,
the company trains Chinese farmers in the proper use of crop
protection products.
Bayer MaterialScience strives to further improve cooperation with
Chinese customers in the development of new applications. To this
end, BMS is expanding the Polymers Research and Development
Center in Shanghai-Pudong, Wenning explained. The aim is to
create an innovative “campus” for all BMS products and
applications that is unique in the world.
Sustainable development applies to Bayer worldwide
Wenning emphasized the importance of sustainable-development
principles. Bayer strives to uphold the highest possible
standards in health, safety and environmental compatibility. This
applies worldwide and is thus also valid for the facilities at
the Shanghai site, Wenning said, with social responsibility being
another fundamental aspect of Bayer’s corporate policy.
The Bayer Management Board Chairman thanked the Chinese
authorities, particularly the Shanghai city administration,
saying their cooperation and support are essential to the project’s successful implementation.
Wenning also had special words of appreciation for Bayer’s employees and partners, whom he
thanked for their enduring cooperation, dedication and
commitment. He said it was that commitment that enabled the
facilities to be inaugurated on schedule.
October 23, 2006 Bayer
Bayer MaterialScience to acquire Taiwan’s Ure-Tech 台湾優得Group
New global leader in thermoplastic polyurethane resins and films
Bayer MaterialScience will acquire Taiwan’s Ure-Tech Group, the largest
thermoplastic polyurethane (TPU) producer in the Asia Pacific
region. With
this acquisition the Germany-based company will become the worldwide
largest supplier and solutions provider of TPU resins and films. The deal is subject to regulatory
approval by the cartel office and is expected to be closed in the
first quarter of 2007. Both parties have agreed not to disclose
purchase price and other related details of the acquisition. In
2005, approximately 180 employees of the Ure-Tech Group generated
sales of around USD 55 million. Sales of Bayer MaterialScience’s Business Unit Thermoplastic
Polyurethanes amounted to 192 million Euros last year with
roughly 450 employees.
Combining its activities with Ure-Tech will substantially
strengthen Bayer MaterialScience’s existing TPU market position in
Asia Pacific, significantly widening and solidifying its market
access, especially in Taiwan, China and the South Asian
countries. It will become the market leader in TPU resins supply
in the Asia Pacific region.
The acquisition will solidly position Bayer MaterialScience to
tap into the significant growth potential for TPU resins in the
Asia Pacific region, especially China. It also provides the
impetus for Bayer MaterialScience to accelerate its global growth
in the TPU resins market. In 2005, the total TPU resins and films
market was worth about 1.2 billion Euros.
Dr. Hagen Noerenberg, Bayer MaterialScience’s Chairman of the Board, said: “We are combining Bayer
MaterialScience’s global expertise, our
international network of customers and locations and our
innovative strength with Ure-Tech’s market access. The company is
the leading Asian supplier of TPU resins and has strong local
expertise as well as close customer relationships.”
“As TPU supplier
and solution provider of resins and films, we aim to be the
number one partner for customers worldwide,”
said Dr. Tim
Bielfeldt, Global Head of Bayer MaterialScience TPU Business
Unit.
Ure-Tech’s CEO, Frank Huang, said: “This is a match made out of
understanding of both our strengths and special know-how. We
complement each other in the areas of production, marketing,
research and development.”
Together with
Ure-Tech’s production facilities, Bayer
MaterialScience will have in close proximity to its customers a
total of six TPU resins and two films production facilities in
North America, Europe, and the Asia Pacific region. Four of these
are in Asia Pacific, in Taichung, Taiwan; Shenzhen in Southern
China; Cuddalore, India; and Osaka, Japan (a joint venture with
Dainippon Ink & Chemicals, Inc.). The other four are in New
Martinsville, West Virginia, USA; South Deerfield, Massachusetts,
USA; and in Dormagen and Bomlitz in Germany. The acquisition of
Ure-Tech’s TPU operations will have no
negative impact on employees.
About Bayer MaterialScience:
With sales of EUR 10.7 billion in 2005, Bayer MaterialScience AG
is one of the world’s largest polymer manufacturers.
Its main fields of activity are the production of high-tech
polymer materials and the development of innovative solutions for
products used in many areas of everyday life. The main consumer
sectors are the automotive, electrical/electronics, construction,
sports and leisure industries. Bayer MaterialScience has
production facilities at 40 sites around the world and a
workforce of approx. 18,800. Bayer MaterialScience is part of the
Bayer Group.
About Ure-Tech:
Taiwan-based Ure-Tech group is the biggest producer of
Thermoplastic Polyurethane (TPU) elastomer in Asia Pacific,
manufacturing products under the Utechllan(R) brand. It was
founded in May 1992 and now has a manufacturing plant in
Taichung, Taiwan, and another production facility in Shenzhen,
China. Its UtechllanR brand of TPU is widely used by the footwear
and sports and leisure industries among others in the Asia
Pacific region.
TAIWAN URE-TECH CO.,LTD. was found in May 1992. Head office is located in Chang Hwa Coast Industrial Park in Chang Hwa, Taiwan. We are a professional manufacturer of Thermoplastic Polyurethane (TPU) elastomer. The
commercial name of products is "Utechllan(R)". Office in Shenzhen, China was established in Oct. 1998. In order to serve the local customers, we have established XUDE RUBBER (SHENZHEN) CO.,LTD. and manufactured products since Sep.2002.
http://www.uretech.com.tw/eng/eng_company_profile.htm
Auction process
successfully concluded:Bayer sells H.C. Starck to Advent
International and The Carlyle Group for EUR 1.2 billion
Proceeds will help to finance the Schering acquisition /
Acquirers plan expansion of H.C. Starck business /
Goal is to position the company for an initial public offering in
3 to 5 years
The Bayer Group plans to sell its subsidiary H.C. Starck to a
consortium formed by financial investors Advent
International and The Carlyle Group for approximately EUR 1.2
billion. As planned, the proceeds will help to finance the
acquisition of Schering. Commenting on the transaction,
Bayer Management Board Chairman Werner Wenning said: “We are convinced that H.C. Starck
will have very good development prospects under the new owners.”
The transaction
value comprises a cash component of more than EUR 700 million and
the assumption of financial liabilities and personnel-related
commitments totaling some EUR 450 million. The divestment thus
reduces Bayer’s net debt by about EUR 1 billion,
with an accounting gain of about EUR 150 million. Closing is
planned to take place at the beginning of 2007, subject to the
approval of the antitrust authorities.
Advent and Carlyle intend to continue developing the H.C. Starck
business, with the aim of positioning the company for an initial
public offering in three to five years. Gregor Bohm, Carlyle
Managing Director in Munich, said: “We’re delighted to be investing in
such a first-class company. H.C. Starck is an extremely
innovative and highly specialized enterprise with excellent
positions in its various markets. We look forward to working with
the entire team to help grow H.C. Starck for the benefit of the
company and its employees.”
Ralf Huep, General
Manager at Advent International in Frankfurt, commented: “H.C. Starck is a highly attractive
investment. It not only holds leadership positions in its
markets, but also has enormous growth potential, both in existing
and prospective new business areas. We will work closely with
management and Carlyle to leverage these strengths and continue
the successful development of H.C. Starck’s business.”
Bayer conducted the
sale of H.C. Starck as an auction process. Several of the many prospective
acquirers were invited to examine the company in detail and
submit a binding offer. Both strategic and financial investors
participated in the bidding through the final stage.
H.C. Starck, headquartered in Goslar in northern Germany,
manufactures metal and ceramic powders,
specialty chemicals,
and parts made from advanced ceramics and refractory metals. The
company employs some 3,400 people and last year posted sales of
EUR 920 million. H.C. Starck has 15 sites in Europe, Asia and
North America.
“Advent
and Carlyle are ideal partners for our future expansion,”
explained H.C.
Starck Managing Director Dr. Heinz Heumuller. “With their support we will
continue to pursue our corporate strategy and business objectives
and work to further improve performance.”
Bayer announced in
March 2006 that it would divest its subsidiaries H.C.
Starck and Wolff
Walsrode
and use the proceeds to partly finance the Schering acquisition.
The two companies have so far been part of the Bayer
MaterialScience subgroup, which will focus in future on
its core businesses.
About Advent International:
Advent International is one of the world’s leading private equity firms,
with over EUR 8 billion (US$ 10 billion) in cumulative capital
raised and offices in 14 countries across Western and Central
Europe, North America, Latin America and Asia. Since its
inception in 1984, Advent has invested in more than 500 companies
in 35 countries and has taken over 130 of these businesses public
on major stock exchanges worldwide. Advent has a proven track
record of success in the German market, having concluded eight
transactions in the past two years. In 2004, for example, Advent
and Carlyle jointly acquired HT Troplast, the world’s leading manufacturer of vinyl
profiles for windows and doors.
(bought Vinnolit GmbH & Co. KG)
About The Carlyle Group:
The Carlyle Group is a global private equity firm with more than
US$ 46 billion (EUR 36 billion) under management. Carlyle invests
in buyouts, venture and growth capital, real estate and leveraged
finance in North America, Europe and Asia. Focus industries are
aerospace, automotive & transportation, consumer &
retail, chemicals, energy & power, healthcare, industrial,
technology & business services, and telecom & media.
Since 1987, Carlyle has invested total equity capital of US$24
billion (EUR 19 billion) in 576 transactions.
H.C. Starck is an international group of companies with more than 3,400 employees at 14 production sites in Europe, North America and the Far East. 非鉄金属及び希少金属・化合物・セラミックス粉末等の分野で世界に名高いメーカーであるドイツ・スタルク社
H.C. Starck produces an assortment of refractory metal powders that is unique the world over, including tungsten, molybdenum, tantalum, niobium, rhenium as well as their compounds (borides, carbides, nitrides, oxides, silicides, sulfides). A further production focus centers on thermal spray and advanced ceramic powders, nonferrous metals, such as nickel and nickel salts, as well as boron and boron compounds.
In addition to metal powders, semi-finished and finished molybdenum, tungsten, tantalum, niobium, titanium, zirconium and nickel products and their alloys are manufactured. Further to the production of standard components, H.C. Starck is your partner for the manufacture of components according to customers' specifications. Our experts provide answers and solutions to your challenges and problems in all areas ranging from construction to alloying, especially for customized components. As a further service H.C. Starck offers the extrusion of molybdenum and TZM.
H.C. Starck is also a leading supplier of specialty chemicals and products formulated for the electronics industry.
In the engineering ceramics sector H.C. Starck has a wide assortment of ceramic intermediates. Its subsidiary H.C. Starck Ceramics GmbH & Co. KG manufactures machine and engine components, anti-friction bearing components and foundry products made of silicon carbide, silicon nitride, aluminum titanate as well as zirconium and aluminum oxide according to customers' specifications. The H.C. Starck Ceramics R&D laboratory also conducts material tests and process developments for customers.
H.C. Starck became a member of the Bayer Group in 1986 and maintains certified Quality Management Systems at all of its sites. Many locations also have Environment Management Systems.
With its almost 200-year history, the Wolff Walsrode AG is one of Bayer's most traditional production sites. As a holding company, Wolff Walsrode operates the Competence Center for cellulose chemistry and markets the Walsrode Industrial Park (which is now open to outside companies), one of the most highly regarded economic locations in Lower Saxony.
The company has transferred its operations to the independent companies Wolff Cellulosics and CaseTech and the technical service provider Probis. It is particularly strong in the field of cellulose derivatives and services such as engineering, utilities, technical service, logistics, waste management and environmental protection, supporting Bayer Material Science in many key entrepreneurial functions. In this capacity, it makes a vital contribution to enabling its parent company to successfully assert itself as an innovative manufacturer. The CEO of Wolff Walsrode, Dr. Dieter Herzog, has no doubts whatsoever: "We play an important role within the Bayer MaterialScience group and are the driver for technological progress in the field of cellulose chemistry."
Our everyday life would be inconceivable without cellulose derivatives, which are used in a vast number of different products. They serve as thickeners in building materials such as tile adhesives, plasters and emulsion paints and also in foodstuffs, cosmetics and pharmaceuticals, and as binders in printing inks and surface coatings.
With its 1,270 employees, the Wolff Walsrode company posted sales last year of around EUR 329 million.
Bayer
2006/12/7
Bayer MaterialScience Expands Production Network in Asia
World’s biggest
global polycarbonate supplier
provides fast local service / Additional EUR 80 million invested
in China and India
As demand for Makrolon(R) continues to rise, Bayer
MaterialScience AG is steadily increasing polycarbonate
production around the world. And at the end of 2006, the company
will be producing 1,200,000 tons of Makrolon a year.
Additional international spending of around EUR 80 million is to
be invested to build up a network in Asia in the next few years,
allowing the company to offer excellent technical service locally
and supply customers quickly and flexibly. The investments will
be used, for example, to build additional
compounding plants in China and India.
Furthermore, a Color Competence Center (CCC) is to be
built at the compounding plant in
Shanghai, which has been in production since
2005. Combined with the Polymer Research and Development Center
in Pudong, Shanghai, the region will become an important center
for Asian and Chinese customers.
Baytown (United States) 260 kt Antwerp (Belgium) 240 kt Uerdingen (Germany) 330 kt Map Ta Phut (Thailand) 270 kt Shanghai 100 kt total 1,200 kt
A
compounding plant with an integrated Color Competence Center is
to come into operation in southern China in the first half of
2008. The next step, planned for the end of 2008, is to use the
same concept to invest in Bayer MaterialScience’s new
site in New Delhi (India). In this way, several locations in Asia
will be added to the successful network of existing compounding
plants with integrated Color Competence Centers in Filago
(Italy), Newark (Ohio, United States) and Map Ta Phut (Thailand).
Thanks to these investments in China, southern China and India,
Dr. Gunter Hilken, head of the Polycarbonates Business Unit at
Bayer MaterialScience, is convinced that his sector is well
equipped to deal with whatever the future holds: ”As a
solution provider we do everything in our power to provide users
of plastics with optimum support during both development and
production. This means we have to be close to our customers in
terms of geographical location, too. We want them to benefit from
our technology network and from the security and stability of a
global corporation, without having to forgo fast, local service.
At the same time, we offer a complete range of polycarbonate
products and are the driving force behind innovation in our
industry sector.”
To keep pace with market demand
for Makrolon, Bayer MaterialScience increased the capacity at its
existing large-scale plants by a total of 170,000 tons between
2004 and 2005. The annual capacity is split among sites in Baytown
(United States) providing 260 kt, Antwerp (Belgium) 240 kt,
Uerdingen (Germany) 330 kt, and Map Ta Phut (Thailand) 270 kt.
Commissioning the new plants at the Shanghai
integrated production site in 2006 achieved an additional annual
capacity of 100 kt for the fast-growing market in
Asia. Due to the continued increase in demand, this additional
capacity is to be doubled during 2008. When capacities for
Makrolon production are added together, Bayer MaterialScience
produces 1.2 million tons of Makrolon a year, making it the
biggest manufacturer of polycarbonates in the world.
Thanks to its exceptional characteristics, Makrolon is the
material of choice for many high-tech applications in the
electrical engineering and electronics industry, the construction
sector, the automotive industry and in the field of packaging and
medical products. It is practically unbreakable, lightweight,
impact resistant even at low temperatures, as transparent as
glass and displays a high level of heat resistance. Polycarbonate
is mixed with other plastics to produce a diverse range of
applications and is offered as blends. Polycarbonate films and
sheets are also becoming increasingly important.
With sales of EUR 10.7 billion in 2005, Bayer MaterialScience AG
is one of the world’s largest
polymer manufacturers. Its main fields of activity are the
production of high-tech polymer materials and the development of
innovative solutions for products used in many areas of everyday
life. The main consumer sectors are the automotive,
electrical/electronics, construction, sports and leisure
industries. Bayer MaterialScience has production facilities at 40
sites around the world and a workforce of approx. 18,800. Bayer
MaterialScience is part of the Bayer Group.
Bayer December 12, 2006
Bayer MaterialScience expands MDI production capacity in
Tarragona to 150,000 tons a year
Location is key component of global production network
Bayer MaterialScience AG has now completed the expansion of its
production facilities for methylene diphenyl diisocyanate
(MDI) in Tarragona, Spain by 50,000 tons a year to an annual
capacity of 150,000 tons. As a result, the company has a
global production capacity of almost 1.1 million tons per year.
Plant capacity at Tarragona for the intermediates carbon monoxide
(CO) and methylene diphenyl diamine (MDA) has also been expanded.
“This
expansion is our response to the growing demand for MDI in
Eastern and Western Europe and the Middle East,”
says Peter
Vanacker, head of the Polyurethanes Business Unit at Bayer
MaterialScience. “We are thereby underlining our
leading position in the polyurethane industry and are now in a
position to provide even better service and support for our
customers as they continue to grow. Furthermore, as a key
location in our global production network, Tarragona will
continue to supply customers in other regions as well.”
MDI production
facilities in Krefeld-Uerdingen (Germany) were
also expanded in summer 2006 by 36,000 tons to a capacity of
200,000 tons a
year. At its integrated Shanghai site, Bayer MaterialScience is
currently building world-scale production facilities capable of
producing 350,000 tons of MDI each year. The facilities are to
start operating in 2008 and will mainly supply customers in the
Asia-Pacific region. A splitter used to extract monomeric and
polymeric MDI from crude MDI that has a plant capacity of 80,000
tons a year went into operation there in June 2006. Bayer
MaterialScience also operates production facilities for MDI in Brunsbuttel
(Germany), Baytown and New Martinsville (both United States),
Belford Roxo (Brazil) and Niihama (Japan).
With sales of EUR 10.7 billion in 2005, Bayer MaterialScience AG
is one of the world’s largest polymer manufacturers.
Its main fields of activity are the production of high-tech
polymer materials and the development of innovative solutions for
products used in many areas of everyday life. The main consumer
sectors are the automotive, electrical/electronics, construction,
sports and leisure industries. Bayer MaterialScience has
production facilities at 40 sites around the world and a
workforce of approx. 18,800. Bayer MaterialScience is part of the
Bayer Group.
February 7, 2007 Bayer
First facility of its kind in China:
Bayer establishes APAC spray competency center in Shanghai
Strong growth for composite materials in China
Bayer MaterialScience has set up a spray competency center in
Shanghai, China, to demonstrate its expertise in polyurethane
spray technology in the Asia Pacific region. It features
state-of-the-art processes and technologies for reinforced and
un-reinforced systems. The spray competency center, located
within Bayer MaterialScience’s Polymer Research &
Development Center (PRDC) in Shanghai, is one of three regional
facilities established globally by Bayer MaterialScience.
“The
center reflects Bayer’s leadership in the field of
polyurethanes spray competency,” said Dr. Thomas Braig, Asia
Pacific Marketing Director for BaySystems Molded Parts &
Elastomers of Bayer MaterialScience. “At our spray competency center, we
bring together both high-tech spray machines, as well as our
advanced polyurethane spray systems. Our aim is to optimally
support our customers in the development of applications based on
our full range of polyurethane spray systems.”
In addition to the
BaytecR Reactive polyurethane system, a thick, high quality film
coating used to waterproof buildings and to protect bridges,
truck beds and other large structured parts against corrosion,
the spray center also features Bayer MaterialScience’s MultitecR and BaypregR
polyurethane spray technologies.
“Both
technologies stand for highly versatile polyurethane spray
systems that enable the efficient production of high-performance,
light-weight composite structures based on polyurethanes,”
said Roy Lin, Head
of Business Development for BaySystems Molded Parts &
Elastomers, and Automotive Systems. “They allow for efficient
wet-in-wet manufacturing with easy handling, without any need for
post-curing. Additionally, our spray system is solvent- and
styrene monomer-free. This environmental friendly technology is
beneficial for all customers, in particular for export business
to Europe and the US,” he noted.
Examples of MultitecR application areas are bathtubs, tractor
fenders and other molded parts which require a high quality
surface top layer with reinforced structure. The BaypregR spray
system is processed in a mold that can be combined with a wide
range of reinforced cores, such as glass, carbon fiber,
polystyrene, or honey comb, enabling a high-performance and
light-weight composite solution. There are various application
examples of the spray system in the automotive and truck
industry, as well as in surf and ski boards and even furniture
parts.
Braig noted how such applications have contributed to the growth
in demand for composite materials. “Demand for composite materials has
grown rapidly in recent years, and has exceeded 10 percent annual
growth rates in markets such as China,”
Braig said. “Our polyurethane systems MultitecR
and BaypregR offer significant advantages in terms of quality,
productivity and efficiency, as well as
environmental-friendliness, compared to conventional fiber
reinforced plastics based on unsaturated polyester or epoxy
resins. Our polyurethane spray systems are the right solution for
all customers who want to be competitively prepared for the
future. With the spray center, we are prepared to support them.”
With 2005 sales of
10.7 billion euros, Bayer MaterialScience AG is among the world’s largest polymer companies.
Business activities are focused on the manufacture of high-tech
polymer materials and the development of innovative solutions for
products used in many areas of daily life. The main segments
served are the automotive, electrical and electronics,
construction and the sports and leisure industries. At the end of
2005, Bayer MaterialScience employed approximately 18,800 people
at 40 production sites around the globe. Bayer MaterialScience is
a Bayer Group company.
Bayer builds world's largest production plant for carbon nanotubes in Chempark Leverkusen
Bayer MaterialScience has
begun work on the construction of a new facility for the production of
carbon nanotubes (CNTs) in Chempark Leverkusen. The new plant will have a
capacity of 200 tons/year, making it the largest of its kind
in the world. The company is to invest around EUR 22 million in
the planning, development and construction of the plant, which
will create 20 new jobs. "We are investing in a key
technology of the future that will open up a broad range of new
applications for us. We intend to utilize this opportunity to the
full. At the same time, the construction of the new CNT facility
is a declaration of faith in Leverkusen and the State of North
Rhine-Westphalia as an industrial location," said Dr.
Wolfgang Plischke, the member of the Bayer AG Board of Management
responsible for innovation, technology and the environment, at a
press conference to mark the start of construction. Current
forecasts predict that the global market for carbon nanotubes
will grow by 25 percent a year. In ten years, annual sales of
these products are expected to reach US-Dollar 2 billion.
Following the official start of construction work,
representatives of the Innovationsallianz "CNT - carbon
nanomaterials conquer markets" - in brief: Inno.CNT - met in
Chempark Leverkusen for their kick-off event. In this alliance,
which is supported by the German Federal Ministry for Education
and Research (BMBF), more than 70 partners from industry and
science have joined together to develop new technologies and
applications for CNT-based materials.
Bayer MaterialScience is one of the few companies that can
produce carbon nanotubes of consistently high quality on an
industrial scale. A pilot plant with an annual capacity of 60
tons has been in operation in Laufenburg in southern Germany
since 2007. Production involves a catalytic process in which the
carbon nanotubes are obtained from a carbon-containing gas at
elevated temperature in a reactor. "Bayer is investing in
this, the world's largest CNT production plant, because we are
convinced of the technological and economic efficiency of the
process," said Plischke.
With the company's know-how, Bayer can now take a product from
the research laboratory and smooth its progress into a broad
spectrum of applications relevant to society, such as energy, the
environment, mobility, safety and construction. Baytubes®
? the brand name
for Bayer's carbon nanotubes ? are already being used to produce
tough, extremely strong, lightweight materials. This means, for
example, that rotor blades for wind turbines are more
energy-efficient, that transport containers weigh less and that
sports equipment can be made more robust.
Innovationsallianz CNT to enhance competitiveness
Plischke also welcomed Thomas Rachel, Parliamentary State
Secretary in the BMBF ? the ministry backing the project ? to the
event. Future developments in the field of CNT-based materials
are to focus on applications involving energy and the
environment, mobility and lightweight construction. A total of
EUR 80 million will be invested in research and development as
part of Inno.CT, of which the BMBF will contribute about EUR 40
million. In addition, the participating companies want to invest
up to EUR 200 million in the further development of these
technologies and applications during the course of the projects
and also after their conclusion.
Rachel pointed out that Germany and the European Union had set
themselves ambitious climate targets. To achieve them, he said,
efficient and responsible energy management was essential. The
German government wanted to significantly reduce energy
consumption in Germany by 2020, and new materials would make a
major contribution to this.
Rachel: "Carbon nanotubes will play a particularly important
role. They offer all kinds of benefits, such as improving fuel
and battery technologies and reducing the weight of vehicles. To
exploit the enormous potential of these new materials, the German
Federal Ministry for Education and Research will fund the
Innovationsallianz CNT to the tune of around EUR 40 million over
a period of four years. This alliance will play a significant
part in implementing the Federal government's high-tech strategy,
through which we aim to strengthen Germany's
competitiveness."
The main purpose of the two-day kick-off event in Leverkusen for
the alliance partners was to exchange technical ideas and
coordinate further cooperation on the project.